

1 **Active remodeling of the chromatin landscape directs extravillous trophoblast cell**
2 **lineage development**

3

4 Kaela M. Varberg^{1,2,*†}, Esteban M. Dominguez^{1,2,†}, Boryana Koseva³, Joseph M. Varberg⁴, Ross
5 P. McNally^{1,2,‡}, Ayelen Moreno-Irusta^{1,2}, Emily R. Wesley³, Khursheed Iqbal^{1,2}, Warren A.
6 Cheung³, Carl Schwendinger-Schreck³, Craig Smail³, Hiroaki Okae⁵, Takahiro Arima⁵, Michael
7 Lydic⁶, Kristin Holoch⁶, Courtney Marsh^{1,6}, Michael J. Soares^{1,2,6,7,*}, and Elin Grundberg^{1,2,3,*}

8

9 ¹Institute for Reproductive and Developmental Sciences, University of Kansas Medical Center,
10 Kansas City, Kansas 66160

11 ²Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas
12 City, KS 66160

13 ³Genomic Medicine Center, Children's Mercy Research Institute, Children's Mercy Kansas City,
14 Kansas City, MO 64108

15 ⁴Stowers Institute for Medical Research, Kansas City, MO 64110

16 ⁵Department of Informative Genetics, Environment and Genome Research Center, Tohoku
17 University Graduate School of Medicine, Sendai 980-8575, Japan

18 ⁶Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City,
19 Kansas 66160

20 ⁷Center for Perinatal Research, Children's Mercy Research Institute, Children's Mercy, Kansas
21 City, MO 64108

22 [†]These authors contributed equally

23 [‡]Present address: Department of Obstetrics and Gynecology, Northwestern University Feinberg
24 School of Medicine, Chicago, IL 60611

25

26 ***Correspondence to** kvarberg@kumc.edu; msoares@kumc.edu; egrundberg@cmh.edu

1 **ABSTRACT**

2 The extravillous trophoblast (**EVT**) cell lineage is a key feature of placentation and successful
3 pregnancy. Knowledge of transcriptional regulation driving EVT cell development is limited.
4 Here, we mapped the transcriptome and epigenome landscape as well as chromatin
5 interactions of human trophoblast stem (**TS**) cells and their transition into EVT cells. Integration
6 of chromatin accessibility, long-range chromatin interactions, transcriptomic, and transcription
7 factor (**TF**) binding motif enrichment enabled identification of TFs and regulatory mechanisms
8 associated with EVT cell development. Functional roles for *TFAP2C*, *SNAI1*, and *EPAS1* in the
9 regulation of EVT cell development were elucidated. *EPAS1* was identified as an upstream
10 regulator of key EVT cell TFs, including *ASCL2* and *SNAI1* and together with its target genes,
11 was linked to pregnancy loss and birth weight. Collectively, we have revealed activation of a
12 dynamic regulatory network that provides a framework for understanding EVT cell specification
13 in trophoblast cell lineage development and human placentation.

1 INTRODUCTION

2 Pregnancy disorders such as recurrent pregnancy loss (**RPL**), preeclampsia, intrauterine
3 growth restriction, and preterm birth can be the result of inadequate delivery of maternal blood
4 to the growing fetus, a consequence of insufficient spiral artery remodeling¹. Spiral artery
5 remodeling is largely dependent on the function of a specialized population of trophoblast cells
6 termed extravillous trophoblast (**EVT**) cells². EVT cells are terminally differentiated trophoblast
7 cells that invade into and restructure the uterine compartment, including transforming tightly
8 coiled spiral arterioles into large, distended vessels capable of increasing blood delivery to the
9 developing fetus³. EVT cells take two routes of invasion into the uterine parenchyma: interstitial
10 and endovascular. Interstitial EVT cells migrate within the stromal compartment between the
11 vasculature, whereas endovascular EVT cells invade into vessels where they replace
12 endothelial cells and adopt a pseudo-endothelial phenotype^{2,4}. In addition to increasing blood
13 volume, EVT cell-remodeled spiral arteries decrease blood flow velocity, and consequently
14 shear stress damage to uterine vessels⁵. The contributions of EVT cells to uterine
15 transformation and successful pregnancy imparts importance to understanding the acquisition of
16 an EVT cell fate. To date there is a limited knowledge of regulatory networks controlling EVT
17 cell differentiation.

18 Comparisons of rodent embryonic stem (**ES**) and trophoblast stem (**TS**) cells using an
19 assortment of approaches to characterize the transcriptome and epigenome have helped define
20 the regulatory landscape critical for establishment of the trophoblast cell lineage⁶⁻¹⁴. These
21 insights helped identify core transcription factors (**TFs**) essential for reprogramming mouse
22 fibroblasts into TS cells^{15,16}. Advancements have also been achieved in understanding higher-
23 order regulatory networks controlling aspects of rodent trophoblast cell differentiation, including
24 the identification of putative TF-gene regulated networks^{8,12,17-20}. The execution of similar
25 experimentation regarding human trophoblast cell development would be informative.

1 A range of *in vitro* model systems for investigating human trophoblast cell lineage
2 development have been proffered but all have fallen short in adequately replicating
3 establishment of the EVT cell lineage²¹. A fundamental problem has been in distinguishing
4 features intrinsic to EVT cells from those associated with the immortalization or transformation
5 processes used to establish the *in vitro* models. In 2018, culture conditions needed to maintain
6 human TS cell renewal and to differentiate TS cells into EVT cells were established²². The
7 human TS cell model is robust and has been utilized to provide new insights into the
8 development of the human trophoblast cell lineage^{20,23–26}. However, systematic profiling of open
9 chromatin, chromatin contacts and associated transcriptional signatures in human TS cells and
10 differentiated EVT cells have not been performed to date.

11 To this end, we applied multiple functional genomics approaches using next-generation
12 sequencing (**NGS**) and contrasted the regulatory landscape of trophoblast cells in the stem
13 state and following differentiation into EVT cells using human TS cells as a model²². The
14 experimentation included systematic assessments of the transcriptome by RNA-sequencing
15 (**RNA-Seq**), chromatin accessibility using Assay for Transposase-Accessible Chromatin-
16 sequencing (**ATAC-Seq**), and high throughput chromosome conformation capture (**Hi-C**),
17 respectively. We integrated these analyses to identify higher-order regulation of human EVT cell
18 differentiation, which was validated by histone modifications (chromatin immunoprecipitation-
19 sequencing, **ChIP-Seq**) in the TS cell model and single-cell RNA sequencing (**scRNA-Seq**) of
20 first trimester human placenta samples. Collectively, the analyses provide a rich resource for
21 dissecting functional genomics of placental-related diseases of pregnancy. Using this resource,
22 we identified candidate TFs and demonstrated their critical role in EVT cell lineage development
23 with links to pregnancy complications.

24
25
26

1 RESULTS

2 *An atlas of regulatory DNA and transcriptional profiles of human TS and EVT cells*

3 We developed a comprehensive functional genomics resource of trophoblast cell
4 development by utilizing human TS cells maintained in the stem state and following
5 differentiation to EVT cells²² (**Fig. 1a**). We first performed a time course analysis monitoring the
6 transition from stem state towards EVT cells at four timepoints [stem state (day 0), day 3, day 6,
7 and day 8]. We noted clear differences in global gene expression at day 0, 3, and 6 (**Fig. 1b**).
8 Expression profiles were more similar at days 6 and 8 of EVT cell differentiation. The
9 upregulated genes included expression of commonly used EVT lineage markers²⁰ (**Fig. 1c**,
10 **Supplementary Fig. 1a**), as well as induction of *HLA-G* (**Fig. 1d**, **Supplementary Fig. 1b**,
11 **Supplementary Fig. 2**). Similarly, morphological changes as TS cells transition from discrete
12 colonies into individual, elongated EVT cells were verified and most pronounced at day 8 (**Fig.**
13 **1e**, **Supplementary Fig. 1b**). Based on these results, we focused on the stem state and EVT
14 cells following eight days of differentiation (day 8) and generated RNA-Seq and ATAC-Seq
15 profiles for multiple replicates of two TS cell lines: CT27 (46, XX) and CT29 (46 XY)
16 (**Supplementary Table 1**). Overall, we identified 2938 transcripts that were significantly
17 upregulated (log₂ fold change >1, adjusted p<0.05) in EVT cells compared to trophoblast cells
18 in the stem state and 3055 transcripts that were significantly downregulated (**Supplementary**
19 **Table 2, Fig. 1f**). The robustness and consistency of the TS cell model was confirmed in
20 multiple ways. First, TS cell transcriptomes obtained from independent experiments were
21 contrasted to previously reported transcriptomes for the same TS cell line²² (Pearson correlation
22 0.64) (**Supplementary Fig. 3a-b**). Second, transcriptomes and active regulatory regions as
23 assessed by RNA-Seq and ATAC-Seq, from CT27 and CT29 TS cell lines were compared
24 across cell states showing high concordance (**Supplementary Fig. 3c-e**). Finally, we used
25 publicly available single-cell gene expression data from EVT cells (n=693 cells) isolated from
26 normal first trimester placental samples^{27,28} and contrasted with expression profiles of a

1 combined group of other trophoblasts with markers of syncytiotrophoblast (**SCT**) and villous
2 cytotrophoblast (**VCT**) (n=7,834 cells) (**Fig. 2a**). We found high concordance of differentially
3 expressed genes in the TS cell culture model with the *in vivo* data (**Fig. 2b; Supplementary**
4 **Fig. 4**). Similarly, gene set enrichment analysis (**GSEA**) using the top 250 *in vivo* markers of the
5 SCT/VCT and EVT lineages, respectively, from the single-cell gene expression data revealed
6 statistically significant enrichment of expression patterns in the *in vitro* TS cell model
7 corresponding to false discovery (FDR) q value of 0.2% for both EVT and Stem state cells
8 GSEA, respectively (**Fig. 2c-e**).

9 Thus, the *in vitro* human TS cell culture model can be successfully leveraged to gain
10 insight into human EVT cell lineage development. We use CT27 as our reference cell line for all
11 subsequent global and targeted analysis with orthogonal validation in CT29 accordingly.

12

13 *EVT cell differentiation drives global changes in chromatin accessibility*

14 Although reference maps of regulatory DNA have been generated across hundreds of
15 human cell and tissue types and states, trophoblast cell lineage representation within these
16 reference maps is sparse and is restricted to either bulk placental samples or embryonic stem
17 cell-derived trophoblast cells without distinction of specific cell lineages or developmental
18 states^{29,30}. Using ATAC-Seq at high sequencing depth across multiple replicates, we have
19 expanded these resources and provided maps of regulatory regions in the trophoblast cell stem
20 state and following differentiation to EVT cells. We analyzed these regulatory regions in multiple
21 ways. First, we called ATAC-Seq peaks, which are markers of open chromatin, jointly across
22 replicates and identified, at 1% false discovery rate (**FDR**), 165,094 (**Supplementary Table 3a**)
23 and 142,520 (**Supplementary Table 3b**) open chromatin regions in stem and EVT cell
24 developmental states, respectively. We then conservatively assessed shared accessible regions
25 by overlapping specific coordinates and included a minimum one base pair (**bp**) overlap. This
26 conservative assessment identified 63% versus 73% of the accessible regions as shared and

1 37% versus 27% of the regions as unique to the stem state versus EVT cell state, respectively.
2 The accessible regions that were shared between stem and EVT cells were distributed similarly
3 across the genome compared to other reported human tissues and cells, with the majority
4 mapping to intronic (44%) or intergenic (32%) regions and a smaller subset mapping to
5 promoter regions (14%) (**Fig. 3a**). However, when contrasting stem versus EVT cell-specific
6 regions, we noted that the genomic distribution of EVT cell-specific regions was shifted, with a
7 larger proportion mapping to intergenic regions (40% versus 34%) and a smaller proportion
8 mapping to promoter regions (4% versus 8%). This shift points toward increased enhancer-
9 driven gene regulation in EVT versus stem state cells (**Fig. 3a**). These observations are
10 reinforced by contrasting sequence coverage in ATAC-Seq, where the coverage is enriched
11 near transcription start sites (**TSS**) for shared accessible regions, but not for EVT cell-specific
12 regions (**Fig. 3b**).

13 We expanded our annotation of stem and EVT cell open chromatin regions to include
14 the atlas of regulatory DNA that was created from 16 different human tissue types or states²⁹.
15 This extensive atlas was used as a comparative reference standard. We found that as many as
16 97% of shared stem and EVT cell regions were previously annotated to regulatory DNA,
17 including 11% that were specific to placental or embryonic/primitive origin. Interestingly, within
18 accessible chromatin regions that were unique to EVT cells, 17% were placental-or
19 embryonic/primitive specific (**Supplementary Table 3a-b**).

20 To characterize the regulatory regions identified by ATAC-Seq in further detail we
21 integrated CHIP-Seq based histone modification data for stem state and EVT cells and noted
22 enrichment of ATAC-Seq coverage near H3K27ac and H3K4me3 peaks for both stem state and
23 EVT cells, respectively (**Fig. 3c**)

24 To identify consensus regulatory regions that display different chromatin accessibility as
25 an indication of different transcription factor (**TF**) binding patterns in stem versus EVT cells, we
26 next applied an alternative approach that utilized individual ATAC-Seq replicates in stem state

1 cells (n=7) and EVT cells (n=7). The consensus regulatory regions we considered in this
2 analysis were 1) covered by at least 10 counts per million reads, 2) fixed windows of 400 bp in
3 size, 3) mapped to an ATAC-Seq peak, and 4) appeared in more than two of the samples. For
4 the 41,465 identified consensus regions, 40,508 and 38,785 mapped to ATAC-Seq peaks in
5 stem state and EVT cells, respectively, and the individual replicates clustered together with the
6 largest amount of variability attributed to differences between the two cell groups
7 (**Supplementary Fig. 5a-b**). Based on estimated binding affinity measured by differences in
8 ATAC-Seq read densities, we identified a total of 23,504 and 9,334 regions that were
9 differentially enriched (5% FDR) and considered more accessible in the stem state and EVT cell
10 state, respectively. We annotated these regulatory regions using the orthogonal ChIP-Seq
11 based histone modification data for active enhancers (H3K27ac) and promoters (H3K4me3)
12 (**Fig. 3c; Supplementary Table 4a-b**). In all, we found 78% versus 76% of the differentially
13 enriched ATAC-Seq regions to map to an active enhancer (H3K27ac) or promoter (H3K4me3)
14 in stem state versus EVT cells, respectively. However, when considering the epigenetic marks
15 separately we noted a clear difference across the two cell states. Specifically, while 36% of
16 differentially enriched ATAC-Seq regions in the stem state overlapped an active enhancer (**Fig.**
17 **3c**) as many as 65% of the differentially enriched ATAC-Seq regions in the EVT cell state
18 overlapped an active enhancer marked by a H3K27ac peak (**Fig. 3d**). Interestingly, differentially
19 enriched ATAC-Seq regions in the stem state were an order of magnitude more likely to map to
20 a putative poised/bivalent promoter (marked by a H3K4me3 peak without an overlapping
21 H3K27ac peak) than differentially enriched ATAC-Seq regions in the EVT cell state (**Fig. 3c-d**).
22 Bivalent chromatin are characterized by having both repressing and activating role of gene
23 expression regulation with important role in cell differentiation³¹. Although we note that the
24 repressive chromatin mark H3K27me3 is required to fully distinguish a poised/bivalent promoter
25 we speculate that these enriched promoter regions in the stem state may silence genes that will
26 activate EVT differentiation as exemplified for *HLA-G* (**Supplementary Fig. 6b and**

1 **Supplementary Fig. 7a**). On the other hand, the enrichment of H3K27ac peak among the
2 differentially enriched ATAC-Seq regions in the EVT cell state further point to significant
3 increased enhancer-driven gene regulation in EVT versus stem state cells³¹.

4 For the EVT cell differentially accessed regulatory regions, we integrated expression
5 data measured by RNA-Seq for regions mapping within 10kb of the TSS for a gene (n=1,576
6 genes) and also found a striking enrichment of EVT cell-upregulated genes mapping near these
7 EVT cell differentially accessed regulatory regions (log2fold >1; adjusted p<0.05), which
8 corresponded to 2.6-fold enrichment (Chi²=615; Fisher p<0.0001) (**Supplementary Table 5**).
9 We noted that many of these differentially bound active regulatory regions linked to differentially
10 expressed genes were those known to be implicated in the regulation of intrauterine trophoblast
11 cell invasion (e.g., *MMP2*, *HLA-G*, and *ASCL2*) (**Supplementary Fig. 6a-c and Supplementary**
12 **Fig. 7a-c**).

13
14 *Long-range chromatin interactions define unique gene regulation machinery in EVT cells*

15 Regulatory DNA that is specific to EVT cells can provide insight into potential
16 transcriptional regulators of EVT cell differentiation and its associated gene expression profile.
17 Due to the significant enrichment of EVT cell-specific regulatory regions near genes with EVT
18 cell-specific expression patterns, we hypothesized that a subset of these regions would map to
19 super-enhancers. A super-enhancer is operationally defined as a large cluster of transcriptional
20 enhancers in close proximity that drive expression of a gene(s)³². Super-enhancers determine
21 cell identity and can provide insight regarding key TFs underlying the differentiation process^{12,33}.
22 To test this, we used the ATAC-Seq data to identify super-enhancers based on established
23 algorithms³⁴. We identified a total of 1,283 super-enhancers, of which 309 mapped to 611
24 differentially bound ATAC-Seq peaks (**Supplementary Table 6**).

25 To identify long-range chromatin interactions involving EVT cell super-enhancers and
26 regulatory regions identified by ATAC-Seq we performed Hi-C chromatin capture. We obtained

1 long-range intra-chromosomal contacts after aligning and filtering Hi-C read pairs across all Hi-
2 C samples and called chromatin loops at 5 kb resolution (**Fig. 4a**). Using this threshold, we
3 identified 11,999 stem state (**Supplementary Table 7a**) and 14,516 (**Supplementary Table 7b**)
4 EVT cell chromatin loops with a minimum and median distance between anchors corresponding
5 to 30 kb and 260-275 kb, respectively (**Fig. 4b**). These observations are consistent with efforts
6 using other cell models^{35,36}. We found that CCCTC-binding factor (**CTCF**) binding motifs were
7 the most enriched TF binding motifs within the loop anchors (covering 60% of all EVT loop
8 anchors). This observation confirms previous efforts that indicate the important role of CTCF in
9 shaping the three-dimensional structure of the genome^{37,38}, in addition to the function it serves
10 as a transcriptional repressor and insulator³⁵. The validity of the Hi-C chromatin capture was
11 confirmed in the CT29 donor line showing high concordance for both stem state and EVT cell
12 chromatin loops, respectively (**Supplementary Fig. 8a**).

13 To identify long-range chromatin interactions, or Hi-C loops, that are specific to either
14 stem state or EVT cells (i.e., differential loops), Hi-C loops from the stem state were integrated
15 using the same parameters described for EVT cells above (**Fig. 4b-c**). Using previously
16 established algorithms³⁹, we identified 99 and 349 loops to be stem- and EVT-cell specific,
17 respectively (**Supplementary Table 7a-b**). The latter set of differential loops was also shown to
18 be more robust as shown in orthogonal validation analysis (**Supplementary Fig. 8b**). These
19 results point to two major properties of cell-specific, Hi-C loops: 1) they are rare due to strongly
20 conserved chromatin conformation across cell states as shown previously³⁹ and 2) they are
21 more common in EVT cells, which could be indicative of increased enhancer-driven gene
22 regulation (**Fig. 3c**).

23 To examine the enrichment of chromatin accessibility near the Hi-C loop anchors, we
24 integrated reads from the ATAC-Seq peaks from the respective cell types. Among all chromatin
25 loops, we found a clear enrichment of accessible chromatin near the center of the anchors
26 (**Supplementary Fig. 9a-b**). EVT cell-specific loops displayed a similar pattern; however, there

1 was no enrichment of accessible chromatin near the center of the anchors for stem state-
2 specific loops likely due to the low number of loops that were identified (**Supplementary Fig.**
3 **9c-d**).

4 We then focused on the 9,334 EVT cell differentially accessed regulatory regions
5 (**Supplementary Table 4b**) and showed in aggregate analysis an enrichment of these near the
6 center of EVT cell loop anchors (**Fig. 4d**). Specifically, we found that 1,239 EVT cell-specific
7 regions defined by ATAC-Seq overlapped at least one Hi-C loop anchor across a total of 1,518
8 EVT cell Hi-C loops. Interestingly, of the 1,518 EVT cell chromatin loops identified, 119
9 contained differentially bound regulatory regions at both anchors and 1,094 had at least one
10 anchor mapped within 10 kb of a known gene (**Supplementary Table 8a-b**). Among the genes
11 identified with long-range chromatin interactions of regulatory DNA, several have been
12 implicated in EVT cell differentiation and function including *ASCL2*, *MMP2*, and *HLA-G*^{20,40-42}
13 (**Supplementary Fig. 10a-b and Supplementary Fig. 11a-b**). Specifically, we identified a
14 super-enhancer 50 kb upstream of *ASCL2* interacting with its promoter region (**Supplementary**
15 **Fig. 12**).

16

17 *Candidate transcriptional regulators of EVT cell differentiation*

18 To identify transcriptional regulators of EVT cell differentiation we utilized the functional
19 genomics resource in two ways. First, we used three sets of regulatory regions to perform motif
20 enrichment of known TF families compared to the genome background. The regulatory regions
21 included: 1) all differentially enriched EVT cell ATAC-Seq peaks based on estimated TF binding
22 affinity, 2) differentially enriched EVT cell ATAC-Seq peaks based on estimated TF binding
23 affinity mapping to an active enhancer and 3) regions in (1) that overlap a super-enhancer (**Fig.**
24 **3f**). In all three analyses (**Supplementary Table 9**, we found TEA Domain Transcription Factor
25 3 (*TEAD3*) and TEA Domain Transcription Factor 1 (*TEAD1*) as the top two ranked TF DNA
26 binding motifs where both genes were also significantly upregulated in EVT cells (*TEAD3*:

1 log₂fold change=1.6, adjusted p=2E-10; *TEAD1*: log₂ fold change=1.3, adjusted p=1E-3;
2 **Supplementary Table 2**). In addition to *TEAD1* and *TEAD3*, another 18 TF DNA binding motifs
3 were identified among the top-ranking TFs across all sets, including Activator Protein 1 (**AP-1**),
4 Activating Protein 2 (**AP-2**), and GATA TF DNA binding motifs (**Supplementary Table 10**).
5 *TEAD1*⁴³ and *TEAD3* have been linked to trophoblast cell regulation, and a paralog, TEA
6 Domain Transcription Factor 4 (**TEAD4**), is a known determinant of the stem state^{24,44}. *TEAD1*
7 and *TEAD3*, each displayed unique regulatory landscapes specific to the EVT cell state
8 (**Supplementary Fig. 13a-b and Supplementary Fig. 14a-b**). *TEAD1* and *TEAD3* are more
9 highly expressed in EVT cells compared to stem state cells, while *TEAD4* is expressed more
10 highly in the stem state (**Supplementary Fig. 13c**).

11 AP-2 and GATA TFs are known regulators of trophoblast cell development^{45,46}. Indeed,
12 the most significant motif enrichment among EVT-specific super-enhancers following those for
13 the TEAD family members was *TFAP2C* (also referred to as AP-2 gamma), which has
14 previously been implicated in the regulation of early decision making in trophoblast cell lineage
15 development⁴⁶ (**Supplementary Table 9c**). However, the potential contributions of *TFAP2C* to
16 human TS cell maintenance and terminal trophoblast differentiation remain elusive.

17 In our second attempt to identify transcriptional regulators of EVT cell differentiation, we
18 followed-up the top 100 EVT cell-specific chromatin loop-gene associations (**Supplementary**
19 **Table 11**) and used the single-cell gene expression data generated from normal first trimester
20 placental samples for validation (**Fig. 2a**). Approximately 70% of these genes that were found to
21 possess EVT-cell specific gene regulation and significantly upregulated in TS cell-derived EVT
22 showed increased expression in the primary EVT cells from the single-cell dataset in
23 comparison to SCT and VCT cells (**Supplementary Table 11**). We classified these EVT cell-
24 specific genes based on TF status and revealed five TF genes (*ASCL2*, *DLX6*, *SNAI1*, *MYCN*,
25 and *EPAS1*) (**Fig. 5**). The regions surrounding each of the five TFs show evidence of EVT cell-
26 specific regulation (**Fig. 4e, Fig. 8e, Fig. 9e, Supplementary Fig. 12, Supplementary Fig. 15a,**

1 **Supplementary Fig. 16a-c, Supplementary Fig. 21a**). While *ASCL2* contributes to EVT cell
2 differentiation²⁰, the contributions of the other identified TFs in trophoblast cell differentiation are
3 less understood.

4 We investigated the role of *TFAP2C*, *SNAI1* and *EPAS1* in the regulation of trophoblast
5 cell development and EVT differentiation.

6 7 *Functional investigation of transcriptional regulators of EVT cell lineage development*

8 To evaluate the functions of *TFAP2C* in trophoblast cell development, we first localized
9 *TFAP2C* in placental specimens and then performed knockdown experiments in the TS cell
10 model. Using *in situ* hybridization, we found *TFAP2C* to be expressed within the EVT cell
11 column of first trimester human placental specimens (**Fig. 6a**). *TFAP2C* co-localized primarily
12 with *CDH1* (cytotrophoblast marker⁴⁷) and less with *PLAC8* (EVT cell marker)^{40,48} transcripts in
13 EVT cell columns, consistent with its enrichment in the cytotrophoblast/trophoblast progenitor
14 cell population at the base of the column (**Fig. 6a**). To determine expression profiles in the TS
15 cell model, we applied RT-qPCR and western blotting to measure *TFAP2C* transcript and
16 protein levels, respectively. *TFAP2C* transcript is expressed in stem cells and EVT cells (at 8
17 days) at comparable levels (**Fig. 6b**), with slightly higher expression of *TFAP2C* at the protein
18 level in the stem state (**Fig. 6c**). However, results from the time-course analysis were more
19 dynamic and showed a marked upregulation of *TFAP2C* at an early transitional stage in EVT
20 cell differentiation (day 3) (**Fig. 6d**). These observations suggest that *TFAP2C* could be involved
21 in both maintenance of the trophoblast cell stem state and the early stages of EVT cell
22 differentiation.

23 The regulatory landscape surrounding the *TFAP2C* locus shows evidence of active
24 chromatin near TSS of the gene in both stem state and EVT cells. (**Supplementary Fig. 17** and
25 **Supplementary Fig. 18**). To elucidate the function of *TFAP2C* in TS cell differentiation we used
26 a gene silencing approach. *TFAP2C*-specific short hairpin RNA (**shRNA**) stably delivered in the

1 stem state interfered with *TFAP2C* transcript (**Fig. 6e**) and protein expression (**Fig. 6f**). *TFAP2C*
2 disruption inhibited TS cell proliferation, altered TS cell morphology (**Fig. 6g**), and adversely
3 affected cell survival in culture conditions promoting EVT cell differentiation. The effects of
4 *TFAP2C* disruption were consistently observed in the CT29 line (**Supplementary Fig. 19**).
5 Disruption of *TFAP2C* also resulted in broad transcriptomic changes, as identified by RNA-Seq.
6 Consistent with impaired cell proliferation, several known genes contributing to cell cycle
7 progression were downregulated, including *AURKA*, *AURKB*, *PLK1*, *MYC*, *EGR1*, *CDK1*,
8 *CCNA2*, *CCNB1*, and *MKI67* (**Fig. 6h**). Transcript signatures indicative of the stem state (e.g.,
9 *TEAD4*, *PEG3*, and *PEG10*) and EVT cell state (e.g., *IGF2*, *ISM2*, *CDKN1C*, *FOXO4*, *GCM1*,
10 *ASCL2*, *SNAI1*, *FSTL3*, *PLAC8*, and *NOTUM*) were also inhibited (**Fig. 6h**). Notable
11 upregulated genes following *TFAP2C* disruption included *CNN1* and *LAMB3*, which are
12 associated with the stem state, as well as *MMP2*, *MCAM*, and *SPARC*, which are linked to the
13 EVT cell state. Ingenuity pathway analysis of the top 500 differentially regulated genes following
14 *TFAP2C* disruption highlighted kinetochore metaphase signaling, cell cycle control of
15 chromosomal replication, as well as cyclins and cell cycle regulation as the top functional
16 pathways (**Supplementary Fig. 20a**). To assess whether *TFAP2C* is a direct regulator of the
17 differentially expressed genes identified upon silencing, we performed ChIP-Seq in the stem
18 state. While we noted an overall overrepresentation ($\text{Chi}^2=90$; Fisher $p<0.0001$) of TF peaks
19 close to (within 2kb) downregulated genes ($\log_2\text{fold} < -1$; adjusted $p<0.05$) (**Fig. 6h**) the same
20 pattern was not seen for genes upregulated genes ($\log_2\text{fold} > 1$; adjusted $p<0.05$,
21 **Supplementary Fig. 20b**). Overall, we conclude that *TFAP2C* contributes to cell cycle
22 regulation mainly as a transcriptional activator and is critical for maintenance of TS cells in a
23 stem state and early EVT cell lineage development.

24 To evaluate the functions and potential contributions of *SNAI1* and *EPAS1* to EVT cell
25 development, we again localized each target in placental specimens by *in situ* hybridization and
26 performed loss-of-function experiments using the TS cell model in CT27 cells (**Figs. 6-8**) and

1 CT29 cells (**Supplementary Figs. 22-23**). First, we examined the spatial distribution of each TF
2 in first trimester human placental tissue and showed that both TFs were more abundant in distal
3 regions of the EVT column and co-localized with *PLAC8*, a marker of differentiated EVT
4 cells^{40,48} (**Fig. 7a**). *SNAI1* and *EPAS1* (also called HIF2A) were significantly upregulated in EVT
5 cells compared to stem state cells at the transcript (**Fig. 7b-c**) and protein levels (**Fig. 7d**).
6 Taken together, both TFs are expressed in EVT cells *in situ* and following their *in vitro* cell
7 differentiation from TS cells.

8 To assess impacts on EVT cell development, we stably expressed shRNAs specific to
9 each TF in the stem state and then attempted to differentiate the cells into EVT cells using CT27
10 (**Figs. 8-9**) and CT29 cell lines (**Supplementary Figs. 22-23**). shRNAs were identified that
11 significantly inhibited *SNAI1* expression at transcript (**Fig. 8a, Supplementary Fig. 22A**) and
12 protein levels (**Fig. 8b, Supplementary Fig. 22b**). Similarly, *EPAS1*-specific shRNAs
13 significantly inhibited expression at transcript (**Fig. 9a, Supplementary Fig. 23a**) and protein
14 levels (**Fig. 9b, Supplementary Fig. 23b**) in CT27 and CT29 cell lines, respectively.
15 Knockdown of either *SNAI1*, or *EPAS1* were each compatible with maintenance of the TS cell
16 stem state. However, deficits in each TF negatively affected aspects of EVT cell differentiation
17 (**Fig. 8c, Supplementary Fig. 22c**), with *EPAS1* disruption showing the most extensive
18 morphologic impact (**Fig. 9c, Supplementary Fig. 22c**). *EPAS1* knockdown cells consistently
19 failed to exhibit the characteristic elongation normally associated with EVT cell differentiation.

20 Parameters of EVT cell differentiation in control and TF knockdown cells were further
21 investigated using RNA-Seq which revealed that both TFs contributed to the regulation of
22 several genes associated with EVT cell lineage development (**Figs. 8-9**). *SNAI1* disruption led
23 to downregulation of several genes associated with the EVT cell state (e.g., *FLT4*, *LAMA4*,
24 *IGF2*, *ISM2*, *ASCL2*, *FSTL3*, *DLX6*, and *NOTUM*) and upregulation of EVT cell interferon-
25 responsive transcripts (e.g., *IFIT1*, *IFIT2*, *IFIT3*, *IFITM1*, *IFI27*, *IFI35*, *IFIH1*, *OAS2*, *OAS3*, and
26 *MX1*) as well as several stem state-associated transcripts (e.g., *ITGB6*, *GJA1*, *LAMB3*, *F3*, and

1 *TAGLN*) (**Fig. 8d**). Similar transcriptomic changes were observed in CT29 cells following *SNAI1*
2 disruption (**Supplementary Fig. 22d**). IFN-responsive transcript expression appears to be a
3 feature of human trophoblast cell differentiation⁴⁹ and may be associated with repetitive element
4 expression and double stranded RNA stress⁵⁰. Similar to morphological changes, disrupting
5 *EPAS1* had the most extensive impact on the EVT cell transcriptome. Signature EVT cell-
6 specific transcripts were prominently downregulated (e.g., *NOTUM*, *DIO2*, *HTRA1*, *MMP2*,
7 *PDE6H*, *ADAM12*, *MCAM*, *HLA-G*, *ASCL2*, *DLX6*, *DLX5*, *ISM2*, *CCR1*, *SNAI1*, *ITGA1*, and
8 *GCM1*). *GCM1* was recently reported to play an important role in EVT cell development⁵¹. In
9 addition, several stem state markers (*ITGB6*, *LAMB3*, *F3*, *JUN*, *EGLN3*, *CYR61*, and *NPPB*)
10 were upregulated in *EPAS1* disrupted cells (**Fig. 9d**). Similar transcriptomic changes were
11 observed in CT29 cells following *EPAS1* disruption (**Supplementary Fig. 23d**). In summary,
12 disruption of *SNAI1* or *EPAS1* each resulted in downregulation of EVT cell-specific transcripts.

13 Differences among the activities of each TF as a transcriptional repressor versus
14 activator (calculated based on $\text{Log}_2\text{FC} > 3$ or < -3) were evident. *SNAI1* and *EPAS1* had
15 repression to activation ratios of 70:30 and 60:40, respectively. The known repressor actions of
16 *SNAI1*⁵² are consistent with the profile.

17 In addition to the common feature of the TFs impacting known EVT-cell markers, each
18 TF also contributed to the regulation of unique transcript signatures. In fact, pathway analysis
19 performed on the top 500 significantly altered (upregulated or downregulated) genes upon
20 silencing of each TF revealed that the most significant biological function associated with the
21 differentially regulated genes for both TFs was “Migration of Cells” (*SNAI1*: $p=1.5\text{E}-39$; *EPAS1*:
22 $p=8.3\text{E}-49$; **Supplementary Table 12, Supplementary Table 13**). Additional pathway analysis
23 performed on the subset of *EPAS1* gene targets mapping to the “Migration of Cell” function
24 ($n=209$ genes) identified “Invasion of Cells” as another top function ($p=5.3\text{E}-70$). Many genes
25 mapping to this “Invasion of Cells” cluster are known contributors to the regulation of EVT cell
26 invasion into the uterus (**Supplementary Fig. 21b**).

1

2 *EPAS1* is an upstream TF regulator and dysregulated in placenta failure

3 As noted in the functional assays, *EPAS1* disruption had the greatest impact on EVT cell
4 morphology and resulted in the downregulation of multiple key genes involved in EVT cell
5 differentiation and invasion. To test the potential of *EPAS1* to act as a direct transcriptional
6 regulator, we used ATAC-Seq peaks containing *EPAS1* (HIF2A) motifs in EVT cells and
7 intersected with RNA-Seq data from control and *EPAS1* knockdown cells (**Supplementary**
8 **Table 14**). This analysis identified *EPAS1*-regulated genes, as detected by RNA-Seq analysis
9 (\log_2 foldchange <-1; adjusted $p < 0.05$), being significantly correlated with chromatin accessible
10 regions containing *EPAS1* (HIF2A) binding motifs. This corresponded to a 1.5-fold enrichment
11 ($\chi^2=62$; Fisher $p < 0.0001$) when considering all EVT cell peaks and a 2.5-fold enrichment
12 when restricting to those EVT cell peaks with differential binding affinity ($\chi^2=71$; Fisher
13 $p < 0.0001$). Among these putative direct targets of *EPAS1* action were *PLAC8*, *DIO2*, *MMP2*,
14 *MYCN*, *ADAM12*, *HLA-G*, and *DLX6*.

15 As failure of proper EVT cell invasion into the uterine compartment at the maternal fetal
16 interface may lead to pregnancy complications, we next assessed whether there is evidence
17 linking *EPAS1* to adverse pregnancy outcomes such as pregnancy loss⁵³. To this end, single-
18 cell gene expression data was generated from first trimester placental samples (4,787 cells)
19 derived from individuals suffering from idiopathic RPL. Single EVT cells ($n=194$) were profiled,
20 and expression profiles were compared to compatible single-cell expression profiles of EVT
21 cells ($n=693$) from gestational age-matched normal control placental samples (**Supplementary**
22 **Fig. 24**). Of the 2,967 differentially expressed genes (absolute \log_2 fold change > 1 , adjusted
23 $p < 0.05$) identified in EVT cells isolated from RPL specimens (**Supplementary Table 15**),
24 *EPAS1* was ranked among the top 200. Further, *EPAS1* expression was significantly higher in
25 placentas from RPL patients (\log_2 fold change=1.6, adjusted $p=7.2E-9$, **Fig. 9f**).

1 To assess the potential role of *EPAS1* in gene expression dysregulation in RPL, a
2 comparison was performed between upregulated genes identified in EVT cells derived from
3 RPL placentas (log₂ fold change >1; adjusted p<0.05) and genes downregulated by *EPAS1*
4 disruption in TS cell-derived EVT cells (log₂ fold change <-1; adjusted p<0.05). This comparison
5 identified a 1.7-fold enrichment (Chi²=53; Fisher p<0.0001) indicative of common gene targets.
6 Among these genes (i.e., upregulated in RPL and positively regulated by *EPAS1* during EVT
7 cell differentiation) were *NOTUM*, *DIO2*, *ADAM12*, *ITGA1*, *CSH1*, *PAPPA*, *PAPPA2*, *CDKN1C*,
8 *LIFR*, *FN1*, and *FLT1*. Upregulation of *FLT1* has been shown to be linked to *EPAS1*
9 upregulation during hypoxia-induced placental failure⁵⁴ and upregulation of *CDKN1C* has been
10 observed in placental samples derived from pregnancy loss cases⁵³. In all, these RPL
11 associated changes in *EPAS1* driven EVT cell gene expression may reflect an adaptive
12 response of a failing pregnancy. A healthy placenta can be defined by its ability to effectively
13 adapt to stressors within the uterine environment⁵⁵. Pregnancy failure in RPL may be
14 exacerbated because *EPAS1* driven adaptations are insufficient to sustain the pregnancy.

15

16 *Genetic variants at the EPAS1 locus are linked to pregnancy complications*

17 To test the hypothesis of a potential genetic predisposition for pregnancy loss, we
18 accessed summary statistics from genome-wide association studies (**GWAS**) of related
19 phenotypes available in the UK Biobank. In addition to pregnancy loss phenotypes, we also
20 included analysis of maternal and fetal genetic effects on birth weight (**Supplementary Table**
21 **16**) as failure of the placenta can result in fetal growth restriction as well. Using these
22 phenotypes, we computed the odds ratio of the proportion of nominally significant (p<0.05) hits
23 in the *EPAS1* gene region (chr2:46,150,000-46,450,000) encompassing our regulatory elements
24 compared with variants in a randomly selected matched window. We found a striking
25 enrichment of *EPAS1* genetic variants for not only pregnancy loss but also for birth weight
26 compared to background (**Fig. 9e**; **Supplementary Fig. 21a**; **Supplementary Fig. 25**;

1 **Supplementary Table 17**). While there is to our knowledge no other large-scale GWAS done
2 on pregnancy loss that can be used for additional replication, we accessed summary statistics
3 from an independent, similar sized GWAS of birth weight⁵⁶ (N=321,223) and were able to
4 confirm the effect of the *EPAS1* locus (rs17034876; $p_{UKBB}=7.1E-28$ and $p_{Warrington}=3.1E-47$).
5 Finally, we used all loci associated with birth weight (N=273 genes, $p<0.001$) and found a
6 significant link (1.9-fold change, $\text{Chi}^2=32.7$; Fisher $p<0.0001$) between fetal genetic loci for birth
7 weight and genes dysregulated by *EPAS1* disruption (absolute log2fold change >1 , adjusted
8 $p<0.05$). Genes included not only *EPAS1* itself (**Fig. 9e** and **Supplementary Fig. 21a**), but also
9 *FLT1*, *PAPPA*, *PAPPA2*, and *CDKN1C* (**Supplementary Table 18**).
10 To conclude, these predisposing *EPAS1* genetic variants associated with pregnancy
11 complications may lead to *EPAS1* dysregulation, abnormalities in transcriptional control, and
12 ineffective placentation leading to increased risk of placental disorders. However, further
13 mechanistic, and population-based studies are needed to establish these relationships.

14

15 **DISCUSSION**

16 EVT cell invasion into the uterine compartment is a critical component of spiral artery
17 remodeling and successful pregnancy^{2,57}. Despite our understanding of the importance of EVT
18 cell function, our knowledge of the underlying molecular mechanisms driving EVT cell
19 development is limited. Here, we utilized the human TS model²² to track regulatory events
20 controlling EVT cell differentiation and generated an NGS-based functional genomics resource
21 comprising atlases for transcriptomes by RNA-Seq, open and active chromatin by ATAC-Seq
22 and ChIP-Seq of histone modifications, and chromatin interactions by Hi-C. Although, all *in vitro*
23 models have limitations, human TS cells represent a remarkable high fidelity stem cell system
24 with the capacity to exhibit many traits intrinsic to EVT cells developing *in situ*. Later stages of
25 differentiation associated with EVT cells penetrating the uterine parenchyma are unlikely to be
26 captured as well in this cell culture model and would require additional refinements.

1 The NGS datasets from the TS model were used to identify higher order regulatory events
2 driving EVT cell lineage specification including characterization of signature epigenomic
3 landmarks characteristic of EVT cell lineage development. Global epigenomic events were
4 reinforced by inspection at the level of individual genes known to drive EVT cell differentiation
5 (e.g., *ASCL2*)²⁰ and downstream genes responsible for the phenotypic features of an EVT cell
6 (e.g., *MMP2*, and *HLA-G*).

7 The architecture of the epigenome undergoes profound changes as stem cells
8 differentiate into specialized cells^{58,59}. The transformation is apparent at multiple levels. Some
9 chromatin regions become more accessible and other regions are closed to the requisite
10 machinery controlling gene transcription. This regulatory process is facilitated by formation of
11 chromatin loops allowing for long-range interactions of regulatory elements including enhancers
12 and promoters. The net effect is distinct transcript profiles associated with stem versus
13 differentiated cells, resulting in cells possessing different morphologies and functional attributes.
14 These architectural and functional changes are exemplified in human TS cells differentiating into
15 EVT cells. TS cells cultured in the stem state are tightly associated, and cellular efforts are
16 directed to proliferation, whereas differentiation into EVT cells is characterized by cell colony
17 dispersal, the manifestation of prominent cellular extensions, and cell migration. Trophoblast cell
18 differentiation status is further defined by cell-specific patterns of gene expression, chromatin
19 accessibility and long-range chromatin interactions – all occurring in a coordinated manner. This
20 new map of trophoblast-lineage specific regulatory DNA generated here consists not only of
21 distinct active chromatin regions specific to EVT cells but also extends current maps of open
22 chromatin for human cell types and tissues²⁹. Increased chromatin accessibility in EVT cells was
23 enriched in intronic and intergenic regions and linked to increased RNA expression. These
24 observations are in line with reference epigenome mapping efforts²⁹ and point towards
25 pronounced activity of distal regulatory regions (i.e., enhancers) controlling cell lineage
26 development through involvement of master TFs regulating gene expression in EVT cells.

1 Indeed, the appearance of increased enhancer-driven gene regulation in EVT versus stem state
2 cells were confirmed by CHIP-Seq of histone modifications marking active enhancer regions
3 (H3K27ac).

4 Motif enrichment within chromatin accessible regions revealed potential ‘core’ TF-DNA
5 interactions that define the EVT developmental state including *TEAD3* and *TFAP2C*. *TEAD3*
6 was identified in a large integrative analysis of over 100 cell types to bind to enhancers that
7 were specific to embryonic stem cell differentiated into trophoblast by treatment with bone
8 morphogenetic protein 4²⁹. *TFAP2C* is a known regulator of the mouse TS cell stem state^{6,9}.
9 Consistent with these observations we showed that *TFAP2C* is also critical for human TS cell
10 expansion and the onset of EVT cell differentiation. In addition, *TFAP2C* represents a key factor
11 in the derivation of TS cells from fibroblasts and pluripotent stem cells^{15,16,46,60}. A recent
12 CRISPR-Cas9 screen has identified other transcriptional regulators critical to maintaining the TS
13 cell stem state (*ARID3A*, *GATA2*, *TEAD1*, and *GCM1*)⁴³.

14 Our genome-wide integrative analyses with multiple layers of epigenome information
15 including active regulatory regions and their interactions led to the identification of an
16 established TF regulator of EVT cell development, *ASCL2*²⁰. The epigenomic landscape of
17 *ASCL2* changed as trophoblast cells differentiated from the stem state to EVT cells. This
18 transition was characterized by the appearance of a long-range interaction of a super-enhancer
19 with the *ASCL2* promoter. We also identified compelling new TF candidates controlling EVT cell
20 lineage development including *SNAI1*, *DLX6*, *MYCN*, and *EPAS1* – each possessing
21 epigenomic signatures indicative of gene activation in both cultured EVT cells and primary EVT
22 cells. Silencing of *SNAI1* resulted in disruptions in EVT cell development and affected the
23 expression of a subset of transcripts characteristic of EVT cells. *SNAI1* is an established
24 transcriptional repressor with known roles in promoting epithelial to mesenchymal transition⁵²,
25 including a potential involvement in EVT cell development⁶¹. *EPAS1* encodes hypoxia inducible
26 factor 2 alpha (**HIF2A**), a basic helix-loop-helix domain TF, coordinating cellular responses to

1 low oxygen and developmental processes with a connection to trophoblast cell biology⁶². The
2 actions of *EPAS1* on EVT cell development were much more extensive than observed for
3 *SNAI1* and included transcriptional regulation of virtually all transcripts defining the EVT cell
4 phenotype. Interestingly, these transcriptional *EPAS1* targets also included TFs contributing to
5 the regulation of EVT cell differentiation (e.g., *ASCL2* and *SNAI1*). Thus, *EPAS1* can be placed
6 upstream relative to other transcriptional regulators directing EVT cell differentiation (**Fig. 9G**).
7 *EPAS1* mRNA and protein accumulate as EVT cells differentiate and do so independent of low
8 oxygen tensions. Mechanisms controlling EVT cell dependent *EPAS1* transcriptional activation
9 and *EPAS1* (HIF2A) protein stabilization are unknown. Elucidation of factors controlling EVT cell
10 *EPAS1* will add to understanding the regulation of EVT cell differentiation.

11 The biology of *EPAS1* in placentation is complicated. *EPAS1* expression is not restricted
12 to EVT cells. Syncytiotrophoblast also express *EPAS1*^{63,64}. Thus, additional layers of regulation
13 impart specificity for *EPAS1* actions in EVT cells versus syncytiotrophoblast. These disparate
14 actions may be linked to contributions of cell specific co-regulators^{65,66}, canonical versus non-
15 canonical *EPAS1* signaling⁶⁷, or the involvement of other unappreciated modulator(s) of *EPAS1*
16 action. The relevance of *EPAS1* to placentation is evident in its association with placental
17 disease. RPL is characterized by elevated EVT cell *EPAS1* expression. *EPAS1* is also
18 dysregulated in preeclampsia⁶⁸. Under such circumstances, *EPAS1* may be responding to a
19 failed placenta and the ensuing hypoxia. Context is important, and inappropriate *EPAS1* may
20 hinder rather than support placentation. Compromised placental function negatively impacts
21 fetal growth, which is also connected to misexpression of *EPAS1* gene targets and is
22 demonstrated by genetic linkage to low birth weight⁵⁶.

23 In summary, we have provided insights into a trophoblast regulatory network controlling
24 EVT cell lineage development. Datasets generated from this research represent a resource for
25 developing new hypotheses that can be tested *in vitro* with human TS cells and *in vivo* using
26 appropriate animal models. They will also provide a valuable reference dataset for newly

1 established TS cell lines derived from pluripotent stem cells^{46,69,70}. *TFAP2C*, *SNAI1*, and *EPAS1*
2 provide entry points and a framework for understanding EVT cell differentiation and human
3 placentation. The challenge will be to harness this new knowledge to develop effective
4 strategies for diagnosing and treating diseases of placentation.

5

6 **MATERIALS AND METHODS**

7 ***Human TS cell culture***

8 Human TS cells (CT27, 46, XX and CT29, 46, XY)²² were cultured in 100 mm tissue
9 culture dishes coated with 5 µg/mL collagen IV (CB40233, Thermo-Fisher, Waltham, MA).
10 Human TS cells were maintained in Complete human TS cell medium [DMEM/F12 (11320033,
11 Thermo-Fisher), 100 µM 2-mercaptoethanol, 0.2% (vol/vol) fetal bovine serum (**FBS**), 50 U/mL
12 penicillin, 50 µg/mL streptomycin, 0.3% bovine serum albumin (**BSA**, BP9704100, Thermo-
13 Fisher), 1% Insulin-Transferrin-Selenium-Ethanolamine solution (**ITS-X**, vol/vol, Thermo-
14 Fisher)], 1.5 µg/mL L-ascorbic acid (A8960, Sigma-Aldrich, St. Louis, MO), 50 ng/mL epidermal
15 growth factor (**EGF**, E9644, Sigma-Aldrich), 2 µM CHIR99021 (04-0004, Reprocell, Beltsville,
16 MD), 0.5 µM A83-01 (04-0014, Reprocell), 1 µM SB431542 (04-0010, Reprocell), 0.8 mM
17 valproic acid (P4543, Sigma-Aldrich), and 5 µM Y27632 (04-0012-02, Reprocell). EVT cell
18 differentiation was induced by plating human TS cells onto 6-well plates pre-coated with 1
19 µg/mL collagen IV at a density of 80,000 cells per well. Cells were cultured in EVT
20 Differentiation Medium [DMEM/F12 (11320033, Thermo-Fisher), 100 µM 2-mercaptoethanol,,
21 50 U/mL penicillin, 50 µg/mL streptomycin, 0.3% BSA, 1% ITS-X solution (vol/vol)], 100 ng/mL
22 of neuregulin 1 (**NRG1**, 5218SC, Cell Signaling, Danvers, MA), 7.5 µM A83-01 (04-0014,
23 Reprocell, Beltsville, MD), 2.5 µM Y27632, 4% KnockOut Serum Replacement (**KSR**,
24 10828028, Thermo-Fisher), and 2% Matrigel[®] (CB-40234, Thermo-Fisher). On day 3 of EVT cell
25 differentiation, the medium was replaced with EVT Differentiation Medium excluding NRG1 and

1 with a reduced Matrigel[®] concentration of 0.5%. On culture day 6 of EVT cell differentiation, the
2 medium was replaced with EVT Differentiation Medium excluding NRG1 and KSR, and with a
3 Matrigel concentration of 0.5%. Cells were analyzed in the stem state and at days 3, 6, and 8 of
4 EVT cell differentiation.

5 Cells were harvested from plates with trypsin, counted, and viability determined with a
6 Countess II automated cell counter (Thermo-Fisher). Sample replicates with the highest viability
7 and an adequate cell count were selected to be used for ATAC-Seq. Cells used for RNA
8 isolation were centrifuged at 300 g for 8 min, supernatants were removed, and cell pellets were
9 resuspended in 1 mL of TRIzol (15596026, Thermo-Fisher).

10

11 ***Flow cytometric analysis***

12 Cells in culture were washed with phosphate buffered saline (**PBS**), detached with
13 TrypLE Express (12604021, Thermo-Fisher Scientific), and collected in basal culture medium.
14 Cell suspensions were centrifuged, cell pellets were washed with PBS, and resuspended with
15 4% paraformaldehyde in PBS for 20 min at room temperature with gentle agitation. Fixed cell
16 suspensions were centrifuged, and cell pellets were washed twice with PBS and stored at 4°C.
17 Fixed cells were permeabilized with PBS containing 3% BSA and 0.2% Triton X-100 for 30 min
18 at room temperature with gentle agitation. Cells were washed with PBS and blocked with PBS
19 containing 3% BSA for 15 min and then incubated overnight with anti-HLA-G-phycoerythrin
20 (1:1500, 1P-292-C100, Cedarlane Labs) prepared in PBS containing 3% BSA and 0.2% Triton
21 X-100 in the dark at 4°C with gentle agitation. Cells were washed twice with PBS, filtered, and
22 analyzed using a BD LSR II flow cytometer (BD Biosciences) at the University of Kansas
23 Medical Center (**KUMC**) Flow Cytometry Core Laboratory.

24

1 ***Omni-ATAC library preparation, sequencing, and analysis***

2 The Omni-ATAC library preparation was performed on freshly isolated cells according to
3 an established protocol⁷¹ until the post-transposition cleanup step. After cleanup of the
4 transposed DNA was complete, samples were stored at -20°C until library amplification.
5 Samples were subsequently thawed at room temperature and library construction completed.
6 The samples underwent 5 cycles of PCR before an aliquot was used in a quantitative PCR
7 (**qPCR**) reaction to determine whether additional amplification was required. An Applied
8 Biosciences Viia7 Real-Time PCR System (Applied Biosciences, Beverly Hills, CA) was used
9 for qPCR and the number of additional PCR cycles needed was determined from the
10 multicomponent plot, which plots fluorescence versus the number of PCR cycles. The maximum
11 fluorescence for each sample was found from the plot, $\frac{1}{4}$ of the maximum fluorescence value
12 was calculated, and the number of additional PCR cycles needed was calculated by determining
13 the cycle number that reached $\frac{1}{4}$ maximum fluorescence on the graph. In cases where the $\frac{1}{4}$
14 maximum fluorescence value was halfway between two cycle numbers, the lower number of
15 cycles was selected since slight under-amplification was more favorable than overamplification.
16 The original samples were then PCR amplified with their determined number of additional
17 cycles. Cleanup of the samples was performed after PCR amplification according to the
18 published protocol⁷¹. Libraries were quantified using a Qubit dsDNA BR Assay Kit (Q32853,
19 Thermo-Fisher) and the size was determined with a High Sensitivity DNA Bioanalyzer Kit (5067-
20 4626, Agilent, Santa Clara, CA) and sequenced on an Illumina Nova6000Seq paired-end using
21 Nextera Sequencing primers.

22 Basic quality control of raw FASTQ files was performed using HTStream (Version 1.3.2;
23 <https://github.com/s4hts/HTStream>). PhiX reads were removed using hts_SeqScreener with
24 default parameters. Duplicates were removed using hts_SuperDeduper (-e 250000). Adapter
25 sequences were trimmed with hts_AdapterTrimmer (-p 4). Unknown nucleotides (N) were

1 removed using hts_Ntrimmer. Base quality trimming was performed using a minimum average
2 quality score of 20 (-q 20) in a 10-bp sliding window (-w10) with hts_QWindowTrim. Trimmed
3 reads shorter than 50 bp as well as orphaned reads from a pair were removed using
4 hts_LengthFilter (-n -m 50). Reads were aligned to the human genome (GRCh38.86) using
5 BWA mem (Version 0.7.17-r1188). The alignments were shifted using alignmentSieve
6 (deepTools; Version 3.5.1) using the --ATACshift option. Alignments in the ENCODE blacklisted
7 regions (<https://doi.org/10.5281/zenodo.1491733>) were removed using Bedtools intersect (with
8 option `-v``; Version 2.30.0). Peaks for each sample were called independently using the
9 callpeak function in MACS3 (Version 3.0.0a6) with a minimum FDR of 0.01 (-q 0.01). Peak
10 regions were annotated in regard to the genomic feature of their location using HOMER's
11 annotatePeaks.pl script as well as overlap with DNase I hypersensitive sites (min overlap of
12 1bp)²⁹. Unique peaks (e.g., EVT cell) were determined based on complete lack of overlap with a
13 comparing set of peak regions (e.g., stem state).

14 The webtool GREAT was used to retrieve genes with an overlapping regulatory domain,
15 where the regulatory domain of a gene is the region 5 kb upstream and 1 kb downstream of the
16 transcription start site (**TSS**). Additionally, distal gene elements were retrieved where the
17 regulatory domain of the genes extends up to 1 Mb. Finally, each peak was annotated by
18 mapping it to the most significant differentially expressed gene (EVT vs stem) with a TSS within
19 10 kb of the peak region.

20 ATAC-seq read counts per peak were generated using the Bioconductor package
21 DiffBind (Version 3.2.7). Peaks with less than 10 counts per million (**CPM**) were excluded. The
22 differential binding affinity of a region between EVT and stem samples was assessed in the
23 Bioconductor package limma (Version 3.48.3) with an FDR of 0.05.

1 Super-enhancers were called using HOMER (version 4.7.2) findpeaks
2 (<http://homer.ucsd.edu/homer/ngs/peaks.html>) using “-style super” mode.

3

4 ***RNA library preparation, sequencing, and analysis***

5 RNA was isolated with a TRIzol/chloroform precipitation followed by a cleanup with a
6 RNeasy Mini Kit (74104, Qiagen, Germantown, MD). Frozen cell isolates in TRIzol were thawed
7 on ice prior to starting the isolation. Once thawed, the samples were placed at room
8 temperature for 5 min to promote dissociation of nucleoprotein complexes. Next, 200 μ L of
9 chloroform was added to each sample with vigorous shaking for 15 sec. Samples were placed
10 at room temperature for 3 min before centrifugation at 12,000 g for 15 min at 4°C. After
11 centrifugation, the upper, colorless, aqueous phase was removed and transferred to a new 1.5
12 mL tube and 1.5 volumes of 100% ethanol added. Isolates containing ethanol were mixed
13 thoroughly by pipetting and 650 μ l transferred to a RNeasy spin column. The protocol for the
14 RNeasy Mini Kit was then followed to clean the sample post-TRIzol/chloroform extraction. RNA
15 was then quantified using a Qubit RNA BR Assay Kit and RNA integrity assessed using RNA
16 ScreenTape (5067-5577 and 5067-5576, Agilent) on the Agilent TapeStation platform (Agilent)
17 prior to library preparation.

18 RNA libraries were prepared using a TruSeq Stranded RNA HT Sample Prep Kit (RS-
19 122-2303, Illumina) on a Caliper Sciclone G3 platform (PerkinElmer, Waltham, MA). Manual
20 bead cleanup was performed using AMPure XP Beads (A63881, Beckman Coulter, Brea, CA)
21 after library preparation to remove primer-dimers. 1.0x volume of beads was added to the entire
22 library volume. Samples were mixed by pipetting and incubated at room temperature for 5 min
23 before being placed on a magnetic stand until the supernatant cleared. Once clear, the
24 supernatant was removed and discarded, and the beads were washed twice with 80% ethanol

1 while still on the magnet. Any residual ethanol was removed, and the beads were air-dried on
2 the magnet for 5 min at room temperature. Once dry, 30 μ L of Resuspension Buffer was added
3 to each sample, the beads were resuspended by pipetting, and the solution incubated for 2 min
4 at room temperature. Samples were then placed on a magnet until the supernatant was clear.
5 The supernatant was then transferred to a new plate. A Qubit dsDNA BR Assay kit was used to
6 determine the concentration of the library and a Fragment Analyzer Standard Sensitivity NGS
7 Fragment Kit (DNF-473-10000, Agilent) was used to detect the size of the library and to verify
8 removal of excess primer-dimers. Standard Illumina Free-Adapter Blocking was performed on
9 the libraries. Cleaned, adapter-blocked libraries were loaded on a NovaSeq6000 (Illumina, San
10 Diego, CA) with a run configuration of 151x8x8x151 and an average depth of 70 M paired-end
11 reads per library.

12 Raw FASTQ files were trimmed using default parameters (-r 0.1 -d 0.03) in Skewer
13 (Version 0.2.2) and reads shorter than 18 bp were discarded. Transcripts were quantified using
14 Kallisto (Version 0.46.2). Differentially expressed genes at FDR of 0.05 were discovered using
15 the Bioconductor package DESeq2 in R (Version 1.32.0). CT27 and CT29 RNA-sequencing
16 data were processed individually following standard processing.

17

18 ***Histone modification ChIP-Seq and analysis***

19 ChIP was performed on CT27 human TS cells as previously described²² using
20 commercially available ChIP Reagents (Nippon Gene, Tokyo, Japan). The following antibodies
21 were used: H3K4me3 (Clone No. CMA304, MABI0304, MBL International, Woburn, MA), and
22 H3K27ac (MABI0309, Clone No. CMA309, MBL International). The ChIP-Seq library was
23 constructed using the Ovation Ultralow System V2 (NuGEN Technologies, Redwood City, CA)
24 and sequenced on the Illumina HiSeq 2500 platform (Illumina). Basic quality control of raw

1 FASTQ files was performed using HTStream (Version 1.3.2;
2 <https://github.com/s4hts/HTStream>). PhiX reads were removed using hts_SeqScreener with
3 default parameters. Duplicates were removed using hts_SuperDeduper (-e 250000). Adapter
4 sequences were trimmed with hts_AdapterTrimmer (-p 4). Unknown nucleotides (N) were
5 removed using hts_Ntrimmer. Base quality trimming was performed using a minimum average
6 quality score of 20 (-q 20) in a 10-bp sliding window (-w10) with hts_QWindowTrim. Trimmed
7 reads shorter than 50 bp as well as orphaned reads from a pair were removed using
8 hts_LengthFilter (-n -m 50). Reads were aligned to the human genome (GRCh38.86) using
9 BWA mem (Version 0.7.17-r1188). Alignments in the ENCODE blacklisted regions
10 (<https://doi.org/10.5281/zenodo.1491733>) were removed using Bedtools intersect (with option `
11 v`; Version 2.30.0). Peaks for each sample were called independently using the callpeak
12 function in MACS3 (Version 3.0.0a6) with a minimum FDR of 0.01 (-q 0.01).

13

14 ***Chromatin capture by Hi-C***

15 Cells were rinsed with 5 mL of PBS and then 5 mL PBS containing 2% formaldehyde
16 were added and incubated for 10 min. Then, 550 μ L of glycine 1.25 M (final conc 0.125M) were
17 added and incubated for 5 min at room temperature before an additional 15 min incubation on
18 ice. Liquid was removed and cells were rinsed two times with 5 mL ice-cold PBS. Cells were
19 scraped and transferred into 2 mL low bind tubes to have the equivalent of 1×10^6 cells (1 Petri
20 Dish). Nuclei were pelleted at 2,500 rpm for 10 min at 4°C (repeat if necessary) and all
21 supernatant was removed and flash frozen on dry ice and stored at -80°C until ready for use.
22 Crosslinked samples were thawed on ice and prepared for Hi-C using the Arima-HiC kit (Arima
23 Genomics, San Diego, CA). Cross-linking was performed according to the Arima-HiC protocol
24 with the following modifications. At step 5, the incubation at 37°C was increased to a duration of
25 60 min and the samples were maintained overnight at 4°C after step 11. Samples were then

1 cleaned with AMPure XP Beads as described in the protocol and all quantification and quality
2 control steps that required the use of a Qubit were performed using a Qubit dsDNA HS Assay
3 Kit. Proximally ligated DNA (1000 ng/sample) was used as an input into the library preparation
4 protocol. Samples were sheared to 400 bp using a Covaris LE220-plus system using the
5 manufacturer's recommended settings. Sizing was confirmed using a High Sensitivity DNA
6 Bioanalyzer kit. Size-selection as described in the Arima-HiC protocol was followed and the
7 entire size-selected sample was used as input into biotin enrichment and library preparation with
8 a KAPA HyperPrep kit and Roche SeqCap Adapters (7141530001 or 7141548001, Roche).
9 Instead of performing the Arima-HiC quality control step 2, the number of cycles needed for
10 library amplification was determined as follows: perform 10 PCR cycles for 125-200 ng of input,
11 perform 9 PCR cycles for 200-400 ng of input, perform 8 PCR cycles for 400-600 ng of input,
12 and perform 7 cycles of PCR for inputs greater than 600 ng. The completed libraries were then
13 quantified using a Qubit dsDNA BR Assay Kit and the library size was determined with a High
14 Sensitivity DNA Bioanalyzer Kit. Standard Illumina Free-Adapter Blocking was performed on the
15 libraries. Cleaned, adapter-blocked libraries were loaded on a NovaSeq6000 with a run
16 configuration of 151x8x8x151 and an average depth of 900M PE reads per library.

17 To discover chromatin loops the standard Juicer pipeline³⁹ was used where contact
18 maps for each sample were generated using the Arima Genomics fragment map file specific to
19 GRCh38 and default parameters. After merging contact maps for each cell state, stem and EVT,
20 chromatin loops were discovered with HiCCUPS (Juicer Tools Version 1.22.01;³⁹) using a matrix
21 size of 1000 (-m 1000) at 5kb, 10 kb, and 25 kb resolution (-r 25000,10000,5000). Differential
22 loops between EVT and stem were identified using HiCCUPSDiff (Juicer Tools Version
23 1.22.01;³⁹) with a matrix size of 1000 (-m 1000). The chromatin loops as well as the differential
24 loops were filtered to exclude contacts in the ENCODE blacklisted regions (⁷²;
25 <https://doi.org/10.5281/zenodo.1491733>) using Bedtools intersect (with option ``-v``; Version

1 2.30.0;⁷³). Furthermore, genes with a TSS within 10 kb of a loop region were linked to each
2 loop.

3 The Bedtools toolkit was used to compute the depth of coverage of the ATAC read data
4 genome-wide in 100 bp bins, normalizing number of ATAC reads in each bin for every 10 M
5 total reads for a given sample. All bins within 20 kb of either end of each of the EVT and stem
6 cell loops were then extracted. To generate control sets, 1000 randomly selected intervals
7 (chose from chr1-22, X, Y) that do not intersect any of the loops and do not intersect our list of
8 blocked regions were generated. Three different control sets with intervals of size 5 kb, 10 kb
9 and 25 kb were generated. All ATAC bins within 20 kb of the intervals in each of these control
10 sets were extracted.

11 Aggregate contact plots were generated with hicAggregateContacts (HiCExplorer
12 Version 3.7.2)⁷⁴ using intra-chromosomal contacts at the 5-kb resolution. Number of bins was
13 set to 20 and the “obs/exp” transformation was used for the contact matrix. Heatmaps were
14 generated with Juicebox 1.11.08.

15

16 ***Transcription factor motif analysis***

17 Motif analysis for ATAC-Seq data was performed using HOMER’s findMotifsGenome.pl
18 script (option ‘-size-given200’; Version 4.11). Motif analysis for Hi-C data in the chromatin
19 contact regions were also discovered using HOMER’s findMotifsGenome.pl script (option ‘-size
20 given’; Version 4.11;⁷⁵).

21

22

1 ***TFAP2C ChIP-Seq and analysis***

2 ChIP was performed on CT27 human TS cells²² in three replicates using the SimpleChIP
3 Enzymatic Chromatin IP kit (Cell Signaling Technology . Anti-rabbit AP-2 gamma antibodies
4 (2320, Cell Signaling) was used in the analysis. In total of 100 ng of fragmented DNA in 25 μ L of
5 water was used as input in library preparation. A KAPA HyperPrep Kit (07962347001, Roche)
6 was used for library preparation, following the protocol associated with the kit with the following
7 modifications. During end repair and a-tailing, 35 μ L of water was added to the master mix
8 containing 7 μ L of end-repair and a-tailing buffer and 3 μ L of end-repair and a-tailing enzyme.
9 Forty-five μ L of the end-repair and a-tailing master mix was added to each sample and was
10 mixed thoroughly by pipetting. During the adapter ligation step, Illumina TruSeq DNA LT
11 adapters, supplied at 15 μ M, were diluted 1:100 in water and 5 μ L of diluted adapters were
12 added to the sample. A master mix of 30 μ L of ligation buffer and 10 μ L of DNA ligase was
13 made and 40 μ L of ligation master mix was added to each sample. After adapter ligation, a 0.8x
14 bead clean-up was performed using AMPure XP Beads (A63881, Beckman Coulter) with a 10
15 min incubation at room temperature to allow the DNA to bind to the beads and a 7 min
16 incubation after two 80% ethanol washes to allow the beads to dry. Once the beads were dry,
17 the beads were resuspended in 25 μ L of water and incubated at room temperature for 2 min.
18 Twenty μ L of post-ligation sample was then transferred to a new tube to be used in library
19 amplification. The PCR library amplification master mix consisted of 25 μ L of 2x KAPA HiFi
20 HotStart ReadyMix, 1.5 μ L of 10x PCR primer cocktail, and 3.5 μ L of water. Thirty μ L of the
21 PCR master mix was added to each post-ligation sample and 13 cycles of PCR were
22 performed. After library amplification, the library underwent a 0.6/0.8x double-sized size
23 selection with 10 min incubations to allow the library to bind to the beads. Two 80% ethanol
24 washes were performed, and the beads were allowed to dry at room temperature for 2 min.
25 Thirty-six μ L of water was added to the dried beads and was incubated at room temperature for

1 2 min to elute the DNA. Thirty-four μ L of the final, size-selected library was transferred to a new
2 tube. The final library concentration was assessed with a Qubit dsDNA HS Kit (Q32854,
3 Thermo-Fisher), and the final size was determined, centering at approximately 400 bp, with a
4 D1000 ScreenTape and D1000 reagents (5067- 5582 and 5067- 5583, Agilent). Cleaned,
5 adapter-blocked libraries were loaded on a NovaSeq6000 with a run configuration of
6 151x8x8x151 and sequenced to an average depth of 20M PE reads per library. Basic quality
7 control of raw FASTQ files was performed using HTStream (Version 1.3.2;
8 <https://github.com/s4hts/HTStream>). PhiX reads were removed using hts_SeqScreener with
9 default parameters. Duplicates were removed using hts_SuperDeduper (-e 250000). Adapter
10 sequences were trimmed with hts_AdapterTrimmer (-p 4). Unknown nucleotides (N) were
11 removed using hts_Ntrimmer. Base quality trimming was performed using a minimum average
12 quality score of 20 (-q 20) in a 10-bp sliding window (-w10) with hts_QWindowTrim. Trimmed
13 reads shorter than 50 bp as well as orphaned reads from a pair were removed using
14 hts_LengthFilter (-n -m 50). Reads were aligned to the human genome (GRCh38.86) using
15 BWA mem (Version 0.7.17-r1188). Alignments in the ENCODE blacklisted regions
16 (<https://doi.org/10.5281/zenodo.1491733>) were removed using Bedtools intersect (with option `
17 v`; Version 2.30.0). Peaks for each sample were called independently using the callpeak
18 function in MACS3 (Version 3.0.0a6) with a minimum FDR of 0.01 (-q 0.01).

19

20 ***Single-Cell RNA Analysis***

21 *Sample Collection and Processing*

22 Study participants were screened at the University of Kansas Health System Advanced
23 Reproductive Medicine Clinic. Inclusion criteria was age >18 years and <42 years at the time of
24 conception, BMI >18 kg/m² and <30 kg/m², and a history of unexplained RPL with recent

1 diagnosis of miscarriage. Diagnosis of RPL was made using recommendations by the American
2 Society for Reproductive Medicine Practice Committee⁷⁶ with RPL defined as "spontaneous loss
3 of two or more pregnancies." For all patients known etiologies for miscarriage were ruled out
4 before allowing participation in study including: Mullerian anomaly, polycystic ovary disease,
5 thyroid disease, diabetes, coagulopathy, balanced translocation or structural rearrangement
6 from sperm or oocyte contributor, and obesity. Miscarriage was diagnosed using American
7 College of Obstetrician and Gynecologists Committee on Practice⁷⁷, which defines miscarriage
8 as "a nonviable, intrauterine pregnancy with either an empty gestational sac or a gestational sac
9 containing an embryo or fetus without fetal cardiac activity within the first 12 6/7 weeks of
10 gestation." All study participants had transvaginal ultrasound to confirm diagnosis of
11 miscarriage.

12 Product of conception (**POC**) including placental and decidual tissue were collected from
13 the study participants where all samples had normal karyotype based on clinical cytogenetics
14 testing including chromosomal analysis (GTG banded chromosomes analyzed at the 450-550
15 band levels) and array comparative genomic hybridization performed in accordance with current
16 International Standing Committee on Human Cytogenetic Nomenclature (ISCN 2009)
17 (**Supplementary Table 19**).

18 Each sample was rinsed in PBS before the addition of 5 mL of Digestion Medium
19 [DMEM/F12 (11320033, Thermo-Fisher) with 10% FBS, and 100 units/mL of penicillin and 100
20 µg of streptomycin (15140122, Thermo-Fisher) with 2.0 mg/mL collagenase type 1A] and
21 incubated for 50 min at 37°C. The sample was strained through a pre-wetted 100 µm filter in a
22 50 mL conical tube and rinsed twice with 5 mL of DMEM/F12 with 10% FBS and 100 units/mL
23 penicillin and 100 µg/mL streptomycin and centrifuged at 300 x g for 8 min. Cell pellets were
24 resuspended in 1 mL of cold Recovery Cell Culture Freezing Medium (12648010, Thermo-
25 Fisher), and the cell suspension was transferred to a cryogenic storage vial. The cryogenic

1 storage vial was placed in a Corning CoolCell FTS30, which was then placed in a -80°C freezer
2 overnight. Samples were stored at -80°C before being thawed and processed for single-cell
3 RNA-Seq.

4 10X Genomics single-cell capture and sequencing

5 Prior to single-cell capture, samples were thawed in 10 mL of Thawing Medium
6 consisting of DMEM/F-12 (11320033, Thermo-Fisher) supplemented with 10% FBS and 100
7 units/mL of penicillin and 100 µg/mL of streptomycin (15140122, Thermo-Fisher) that was
8 prewarmed in a 37°C bead bath and centrifuged at 300 x g for 8 min. The supernatant was
9 carefully removed without disturbing the cell pellets. The cell pellets were each resuspended in
10 0.5 mL of Thawing Medium, and the cell suspensions were placed on ice and passed through a
11 pre-wetted 40 µm nylon mesh cell strainer. Cell suspensions were centrifuged at 300 x g for 8
12 min at 4°C, and the supernatant was carefully aspirated without disturbing the cell pellets. The
13 cell pellets were resuspended in 100 µL of cold Thawing Medium, and cell count and viability
14 were assessed using 0.4% Trypan Blue and a Countess II automated cell counter. For each
15 sample, Chromium Chip B (100153, 10x Genomics) were loaded (**Supplementary Table 19**).
16 Following cell loading, cDNA and library preparation was performed identically for all samples
17 using the Chromium Single Cell 3' Library & Gel Bead Kit v3 (1000075, 10x Genomics)
18 according to the manufacturer's protocol. Libraries were sequenced using an Illumina NovaSeq
19 6000 using 2x94 cycle paired-end. Sequenced reads were initially processed by the Cell Ranger
20 pipeline which includes FASTQ creation, read alignment, gene counting, and cell calling. The
21 Cell Ranger GRCh38(v2020-A) genome was used as the reference for alignment.

22 Post-sequencing analysis of single-cell RNA datasets

23 The Cell Ranger matrix file from the single-cell RNA sequencing (**scRNA-Seq**) of RPL
24 samples was processed along with the Cell Ranger matrices of two publicly available
25 datasets^{27,28} of gestational age-matched normal control POC samples profiled using the same

1 platform (10X Genomics, **Supplementary Table 19**) using Seurat's standard workflow⁷⁸. Each
2 sample was individually processed with the SCTransform function⁷⁹ using the glmGamPoi
3 package⁸⁰ with capture as a batch variable when applicable. The three datasets were integrated
4 using the standard integration workflow for data normalized with SCTransform⁷⁹ and 3,000
5 integration features were selected for downstream analysis. After integration, linear dimensional
6 reduction, nonlinear dimensional reduction, nearest neighbor finding, and unsupervised
7 clustering were completed according to the standard workflow⁷⁸. Cell type label transfer was
8 performed by referencing the Vento-Tormo dataset²⁸. The predicted cell identities (**ID**) were
9 generated using the FindTransferAnchors and TransferData functions of Seurat⁷⁸. If necessary,
10 cell type labels were manually adjusted based on marker gene expression to exclude
11 ambiguous cell clusters. Cells with greater than 50% mitochondrial reads and less than 2,000
12 molecules were removed from all three datasets. The Vento-Tormo dataset²⁸ had an additional
13 filtering where cells with a mitochondrial ratio of greater than 20% and less than 3500 Unique
14 Molecular Identifiers (**UMIs**) and 1250 unique genes were removed.

15 Differential Expression Analysis

16 For differential expression analysis, genes were filtered according to the parameters
17 used for Vento-Tormo dataset²⁸. The raw UMI counts of samples with multiple captures were
18 summed prior to differential expression analysis.

19 Genes that were expressed in three or more cells per dataset were kept for pseudobulk
20 differential expression analysis. A matrix was aggregated to find the UMI counts by gene per
21 sample ID within a specific cell type. Using the raw counts and metadata of a specific cell type,
22 a DESeq dataset⁸¹ was created, and the counts were transformed by the vst function for
23 principal component analysis. Differential expression testing was performed by the DESeq
24 function with default parameters on the generated DESeq dataset⁸¹. Pairwise differential
25 expression contrasts were performed according to the inferred cell type labels (EVT or

1 SCT/VCT) where Vento-Tormo²⁸ and Suryawanshi²⁷ datasets were combined as the control
2 group. The contrast was performed with the results function from DESeq2 with default
3 parameters (Benjamini-Hochberg p-value adjustment) and alpha equal to 0.05⁸¹. Log2 fold
4 changes were shrunk with the lfcShrink function with the apeglm package^{81,82}. For a gene to be
5 significantly differentially expressed, the Benjamini-Hochberg adjusted p-value was less than
6 0.05.

7 Gene Set Enrichment Analysis

8 The GSEA 4.3.2 software^{83,84} was used using three gene sets (N=250 genes/set
9 representing upregulated genes from scRNA-Seq analysis in EVT and SCT/VCT, respectively,
10 as well as a gene set representing genes not differentially expressed). Normalized gene
11 expression count for each EVT (n=6) and stem (n=6) cell state from the TS cell *in vitro* model
12 was used with EVT and Stem labelled as phenotype 0 and 1, respectively.

13 Data visualization

14 Data from the scRNA-Seq assays were normalized and scaled with the NormalizeData
15 and ScaleData functions of Seurat⁷⁸. Violin plots and feature plots were then generated using
16 default parameters.

17 Ethics Declaration

18 The study was approved by the Children's Mercy Institutional Review Board (Study No.
19 11120514). Informed written consent was obtained from the RPL participants before study
20 inclusion.

21

1 **Human placental specimens**

2 Sections of paraffin-embedded first trimester placenta tissue were obtained from the
3 Lunenfeld-Tanenbaum Research Institute (Mount Sinai Hospital, Toronto, Canada) with written
4 informed consent. Prior approval was granted by the respective local human research ethics
5 review committees at the Mount Sinai Hospital and KUMC.

7 **In situ hybridization**

8 Transcripts for *TFAP2C*, *EPAS1*, *SNAI1*, *PLAC8*, and *CDH1* were localized within
9 human first trimester placental tissue sections. RNAscope Multiplex Fluorescent Reagent Kit
10 version 2 (Advanced Cell Diagnostics) was used for in situ hybridization analysis. Probes were
11 prepared to detect *TFAP2C* (NM_003222.3, 515921, target region: 664-1596), *EPAS1*
12 (NM_001430.4, 410591, target region: 1332-2354), *SNAI1* (NM_005985.3, 560421, target
13 region: 17-1233), *CDH1* (NM_004360.3, 311091-C2, target region: 263-1255), and *PLAC8*
14 (NM_016619.3, 858491-C2, target region: 5-1448). *CDH1* and *PLAC8* probes were used to
15 identify cytotrophoblast/trophoblast progenitor cells and differentiated EVT cells of the EVT cell
16 column, respectively^{47,48}. Fluorescence images were captured on a Nikon 90i upright
17 microscope (Nikon) with a Photometrics CoolSNAP-ES monochrome camera (Roper).

19 **shRNA-mediated gene silencing**

20 Lentivirus-mediated shRNA delivery was used as a tool to test the biological roles for
21 *TFAP2C*, *EPAS1*, and *SNAI1* in human TS cells. Several shRNAs designed for each target
22 were subcloned into pLKO.1 and their efficacy tested by RT-qPCR and western blotting. An
23 shRNA which does not recognize any known mammalian gene, pLKO.1-shSCR (Plasmid 1864)
24 was used as a control (Addgene, Cambridge, MA). Sequences for shRNAs used in the analysis
25 are provided in **Supplementary Table 20**. Construct design, lentivirus production, and lentiviral
26 transduction were performed as previously described²⁰.

1 **Transcript quantification by RT-qPCR**

2 RNA was isolated with TRIzol/chloroform precipitation (15596018, Thermo-Fisher) as
3 previously described²⁰. cDNA was synthesized from 1 µg of total RNA using the High-Capacity
4 cDNA Reverse Transcription Kit (Thermo-Fisher, 4368813) and diluted 10 times with ultra-pure
5 distilled water. qPCR was performed using PowerSYBR Green PCR Master Mix (4367659,
6 Thermo-Fisher) and primers (250 nM each). PCR primer sequences are listed in
7 **Supplementary Table 21**. Amplification and fluorescence detection were measured with a
8 QuantStudio 5 Flex Real-Time PCR System (Thermo-Fisher). An initial step (95°C, 10 min)
9 preceded 40 cycles of a two-step PCR (92°C, 15 s; 60°C, 1 min) and was followed by a
10 dissociation step (95°C, 15 s; 60°C, 15 s; 95°C 15 s). The comparative cycle threshold method
11 was used for relative quantification of the amount of mRNA for each sample normalized to
12 housekeeping genes *B2M* or *POLR2A*. Statistical analyses were performed using GraphPad
13 Prism 8 software. Welch's *t* tests, Brown-Forsythe and Welch ANOVA tests, or Two-way
14 ANOVA tests were applied when appropriate. Data is represented as mean ± standard deviation
15 with the statistical significance level set at $P < 0.05$.

16

17 **Western blotting**

18 Western blotting was performed as previously described²⁰. Briefly, cell lysates were
19 sonicated in radioimmunoprecipitation assay (**RIPA**) lysis buffer (sc-24948A, Santa Cruz
20 Biotechnology, Dallas, TX). Protein concentrations were measured with the DC Protein Assay
21 (5000112, Bio-Rad) and RIPA buffer was used as the blank standard. Proteins were separated
22 by SDS-PAGE and transferred onto polyvinylidene difluoride (**PVDF**) membranes (10600023,
23 GE Healthcare, Chicago, IL). Following the transfer, PVDF membranes were blocked with 5%
24 non-fat milk in Tris-buffered saline with 0.1% Tween 20 (**TBST**) and probed with primary
25 antibodies to SNAI1 (1:1000, 3879S, Cell Signaling Technology), EPAS1 (1:1000, 66731-1-Ig,
26 Proteintech), TFAP2C (1:750, 6E4/4, sc-12762, Santa Cruz Biotechnology), and glyceraldehyde-

1 3-phosphate dehydrogenase (**GAPDH**, 1:5000, AM4300, Thermo-Fisher) overnight at 4°C.
2 PVDF membranes were washed three times for 5 min each with TBST and incubated with
3 secondary antibodies (goat anti-rabbit IgG HRP, 1:5000, 7074S, Cell Signaling Technology and
4 horse anti-mouse IgG HRP, 7076, Cell Signaling Technology) for 1 h at room temperature.
5 Immunoreactive proteins were visualized using the Luminata™ Crescendo Western HRP
6 Substrate (WBLUR0500, Millipore, Billerica, MA) according to the manufacturer's instructions.

7

8 ***RNA-seq analysis for silencing experiment***

9 Stranded mRNA-Seq was performed using the Illumina NovaSeq 6000 Sequencing
10 System at the University of Kansas Medical Center – Genomics Core (Kansas City, KS). Quality
11 control was completed using the Agilent TapeStation 4200 with the RNA ScreenTape Assay kit
12 (Agilent Technologies 5067-5576). Total RNA (1 µg) was used to initiate the library preparation
13 protocol. The total RNA fraction was processed by oligo dT bead capture of mRNA,
14 fragmentation, reverse transcription into cDNA, end repair of cDNA, ligation with the appropriate
15 Unique Dual Index (UDI) adaptors, strand selection, and library amplification by PCR using the
16 Universal Plus mRNA-Seq with NuQuant library preparation kit (0520-A01, Tecan Genomics).
17 Library validation was performed using the D1000 ScreenTape Assay kit (5067-5582, Agilent)
18 on the Agilent TapeStation 4200. The concentration of each library was determined with the
19 NuQuant module of the library prep kit using a Qubit 4 Fluorometer (Thermo-Fisher/Invitrogen).
20 Libraries were pooled based on equal molar amounts and the multiplexed pool was quantified,
21 in triplicate, using the Roche Lightcycler96 with FastStart Essential DNA Green Master
22 (06402712001, Roche 0) and KAPA Library Quant (Illumina) DNA Standards 1-6 (KK4903,
23 KAPA Biosystems). Using the qPCR results, the RNA-Seq library pool was adjusted to 2.125
24 nM for multiplexed sequencing. Pooled libraries were denatured with 0.2 N NaOH (0.04N final
25 concentration) and neutralized with 400 mM Tris-HCl, pH 8.0. A dilution of the pooled libraries to
26 425 pM was performed in the sample tube on the instrument and followed by onboard clonal

1 clustering of the patterned flow cell using the NovaSeq 6000 S1 Reagent Kit (200 cycle)
2 (20012864, Illumina). A 2x101 cycle sequencing profile with dual index reads was completed
3 using the following sequence profile: Read 1 – 101 cycles x Index Read 1 – 8 cycles x Index
4 Read 2 – 8 cycles x Read 2 – 101 cycles. Following collection, sequence data were converted
5 from .bcl file format to fastq file format using bcl2fastq software and de-multiplexed into
6 individual sequences and downstream analysis performed as described above.

7

8 ***GWAS data analysis and integration***

9 Summary statistics from UK Biobank GWAS was accessed at [http://www.nealelab.is/uk-](http://www.nealelab.is/uk-biobank)
10 [biobank](http://www.nealelab.is/uk-biobank). Odds ratio of the proportion of nominally significant ($P < 0.05$) hits in the *EPAS1* gene
11 region (GRCh38; chr2:46,150,000-46,450,000) was computed and compared with variants in a
12 randomly selected matched window. This step was repeated 1000 times for each phenotype to
13 generate a distribution of odds ratio. To compute significance using Wilcoxon test, a null
14 distribution was generated to compare against. For each permutation, another randomly
15 selected matched window size was selected and compared with the first randomly selected
16 region chosen in step 1.

17

18 **DATA AVAILABILITY**

19 Raw and processed sequencing data from ATAC-Seq, RNA-Seq and Hi-C have been
20 submitted to the NCBI Gene Expression Omnibus (GEO). Processed data can be visualized in
21 the UCSC Genome Browser. The ChIP-seq data of histone modifications are deposited in
22 Japanese Genotype-phenotype Archive (JGA).

23

24 **CODE AVAILABILITY**

1 Only publicly available tools were used in data analysis as described wherever relevant
2 in the Methods.

3

4 **REFERENCES**

- 5 1. Brosens, I., Puttemans, P. & Benagiano, G. Placental bed research: I. The placental bed:
6 from spiral arteries remodeling to the great obstetrical syndromes. *Am. J. Obstet. Gynecol.*
7 **221**, 437–456 (2019).
- 8 2. Velicky, P., Knöfler, M. & Pollheimer, J. Function and control of human invasive trophoblast
9 subtypes: Intrinsic vs. maternal control. *Cell Adhes. Migr.* **10**, 154–162 (2016).
- 10 3. Knöfler, M. *et al.* Human placenta and trophoblast development: key molecular mechanisms
11 and model systems. *Cell. Mol. Life Sci. CMLS* **76**, 3479–3496 (2019).
- 12 4. Damsky, C. H. & Fisher, S. J. Trophoblast pseudo-vasculogenesis: faking it with endothelial
13 adhesion receptors. *Curr. Opin. Cell Biol.* **10**, 660–666 (1998).
- 14 5. Burton, G. J., Woods, A. W., Jauniaux, E. & Kingdom, J. C. P. Rheological and physiological
15 consequences of conversion of the maternal spiral arteries for uteroplacental blood flow
16 during human pregnancy. *Placenta* **30**, 473–482 (2009).
- 17 6. Kidder, B. L. & Palmer, S. Examination of transcriptional networks reveals an important role
18 for TCFAP2C, SMARCA4, and EOMES in trophoblast stem cell maintenance. *Genome Res.*
19 **20**, 458–472 (2010).
- 20 7. Rugg-Gunn, P. J., Cox, B. J., Ralston, A. & Rossant, J. Distinct histone modifications in stem
21 cell lines and tissue lineages from the early mouse embryo. *Proc. Natl. Acad. Sci. U. S. A.*
22 **107**, 10783–10790 (2010).
- 23 8. Chuong, E. B., Rumi, M. A. K., Soares, M. J. & Baker, J. C. Endogenous retroviruses function
24 as species-specific enhancer elements in the placenta. *Nat. Genet.* **45**, 325–329 (2013).

- 1 9. Latos, P. A. *et al.* Elf5-centered transcription factor hub controls trophoblast stem cell self-
2 renewal and differentiation through stoichiometry-sensitive shifts in target gene networks.
3 *Genes Dev.* **29**, 2435–2448 (2015).
- 4 10. Latos, P. A. *et al.* Fgf and Esrrb integrate epigenetic and transcriptional networks that
5 regulate self-renewal of trophoblast stem cells. *Nat. Commun.* **6**, 7776 (2015).
- 6 11. Rhee, C. *et al.* Mechanisms of transcription factor-mediated direct reprogramming of mouse
7 embryonic stem cells to trophoblast stem-like cells. *Nucleic Acids Res.* **45**, 10103–10114
8 (2017).
- 9 12. Lee, B.-K. *et al.* Super-enhancer-guided mapping of regulatory networks controlling mouse
10 trophoblast stem cells. *Nat. Commun.* **10**, 4749 (2019).
- 11 13. Schoenfelder, S. *et al.* Divergent wiring of repressive and active chromatin interactions
12 between mouse embryonic and trophoblast lineages. *Nat. Commun.* **9**, 4189 (2018).
- 13 14. Todd, C. D., Deniz, Ö., Taylor, D. & Branco, M. R. Functional evaluation of transposable
14 elements as enhancers in mouse embryonic and trophoblast stem cells. *eLife* **8**, (2019).
- 15 15. Benchetrit, H. *et al.* Extensive nuclear reprogramming underlies lineage conversion into
16 functional trophoblast stem-like cells. *Cell Stem Cell* **17**, 543–556 (2015).
- 17 16. Kubaczka, C. *et al.* Direct induction of trophoblast stem cells from murine fibroblasts. *Cell*
18 *Stem Cell* **17**, 557–568 (2015).
- 19 17. Abell, A. N. *et al.* MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal
20 transition in trophoblast stem cells. *Cell Stem Cell* **8**, 525–537 (2011).
- 21 18. Tuteja, G., Chung, T. & Bejerano, G. Changes in the enhancer landscape during early
22 placental development uncover a trophoblast invasion gene-enhancer network. *Placenta* **37**,
23 45–55 (2016).
- 24 19. Kubota, K., Kent, L. N., Rumi, M. A. K., Roby, K. F. & Soares, M. J. Dynamic regulation of
25 AP-1 transcriptional complexes directs trophoblast differentiation. *Mol. Cell. Biol.* **35**, 3163–
26 3177 (2015).

- 1 20. Varberg, K. M. *et al.* ASCL2 reciprocally controls key trophoblast lineage decisions during
2 hemochorial placenta development. *Proc. Natl. Acad. Sci. U. S. A.* **118**, (2021).
- 3 21. Lee, C. Q. E. *et al.* What is trophoblast? A combination of criteria define human first-
4 trimester trophoblast. *Stem Cell Rep.* **6**, 257–272 (2016).
- 5 22. Okae, H. *et al.* Derivation of human trophoblast stem cells. *Cell Stem Cell* **22**, 50-63.e6
6 (2018).
- 7 23. Takahashi, S. *et al.* Loss of p57KIP2 expression confers resistance to contact inhibition in
8 human androgenetic trophoblast stem cells. *Proc. Natl. Acad. Sci. U. S. A.* (2019)
9 doi:10.1073/pnas.1916019116.
- 10 24. Saha, B. *et al.* TEAD4 ensures postimplantation development by promoting trophoblast self-
11 renewal: An implication in early human pregnancy loss. *Proc. Natl. Acad. Sci. U. S. A.* **117**,
12 17864–17875 (2020).
- 13 25. Perez-Garcia, V. *et al.* Placentation defects are highly prevalent in embryonic lethal mouse
14 mutants. *Nature* **555**, 463–468 (2018).
- 15 26. Muto, M. *et al.* Intersection of regulatory pathways controlling hemostasis and hemochorial
16 placentation. *Proc. Natl. Acad. Sci. U. S. A.* **118**, e2111267118 (2021).
- 17 27. Suryawanshi, H. *et al.* A single-cell survey of the human first-trimester placenta and
18 decidua. *Sci. Adv.* **4**, eaau4788 (2018).
- 19 28. Vento-Tormo, R. *et al.* Single-cell reconstruction of the early maternal-fetal interface in
20 humans. *Nature* **563**, 347–353 (2018).
- 21 29. Meuleman, W. *et al.* Index and biological spectrum of human DNase I hypersensitive sites.
22 *Nature* **584**, 244–251 (2020).
- 23 30. Roadmap Epigenomics Consortium *et al.* Integrative analysis of 111 reference human
24 epigenomes. *Nature* **518**, 317–330 (2015).
- 25 31. Bernstein, B. E. *et al.* A bivalent chromatin structure marks key developmental genes in
26 embryonic stem cells. *Cell* **125**, 315–326 (2006).

- 1 32. Pott, S. & Lieb, J. D. What are super-enhancers? *Nat. Genet.* **47**, 8–12 (2015).
- 2 33. Moorthy, S. D. *et al.* Enhancers and super-enhancers have an equivalent regulatory role in
3 embryonic stem cells through regulation of single or multiple genes. *Genome Res.* **27**, 246–
4 258 (2017).
- 5 34. Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease. *Cell* **155**, 934–
6 947 (2013).
- 7 35. Rao, S. S. P. *et al.* A 3D map of the human genome at kilobase resolution reveals principles
8 of chromatin looping. *Cell* **159**, 1665–1680 (2014).
- 9 36. Greenwald, W. W. *et al.* Subtle changes in chromatin loop contact propensity are associated
10 with differential gene regulation and expression. *Nat. Commun.* **10**, 1054 (2019).
- 11 37. Guelen, L. *et al.* Domain organization of human chromosomes revealed by mapping of
12 nuclear lamina interactions. *Nature* **453**, 948–951 (2008).
- 13 38. Kubo, N. *et al.* Promoter-proximal CTCF binding promotes distal enhancer-dependent gene
14 activation. *Nat. Struct. Mol. Biol.* **28**, 152–161 (2021).
- 15 39. Durand, N. C. *et al.* Juicer Provides a One-Click System for Analyzing Loop-Resolution Hi-C
16 Experiments. *Cell Syst.* **3**, 95–98 (2016).
- 17 40. Morey, R. *et al.* Transcriptomic drivers of differentiation, maturation, and polyploidy in
18 human extravillous trophoblast. *Front. Cell Dev. Biol.* **9**, 702046 (2021).
- 19 41. Liu, Y. *et al.* Single-cell RNA-seq reveals the diversity of trophoblast subtypes and patterns
20 of differentiation in the human placenta. *Cell Res.* **28**, 819–832 (2018).
- 21 42. Meinhardt, G. *et al.* Wnt-dependent T-cell factor-4 controls human extravillous trophoblast
22 motility. *Endocrinology* **155**, 1908–1920 (2014).
- 23 43. Dong, C. *et al.* A genome-wide CRISPR-Cas9 knockout screen identifies essential and
24 growth-restricting genes in human trophoblast stem cells. *Nat. Commun.* **13**, 2548 (2022).

- 1 44. Meinhardt, G. *et al.* Pivotal role of the transcriptional co-activator YAP in trophoblast
2 stemness of the developing human placenta. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 13562–
3 13570 (2020).
- 4 45. Krendl, C. *et al.* GATA2/3-TFAP2A/C transcription factor network couples human pluripotent
5 stem cell differentiation to trophectoderm with repression of pluripotency. *Proc. Natl. Acad.*
6 *Sci. U. S. A.* **114**, E9579–E9588 (2017).
- 7 46. Liu, X. *et al.* Reprogramming roadmap reveals route to human induced trophoblast stem
8 cells. *Nature* **586**, 101–107 (2020).
- 9 47. Renaud, S. J. *et al.* OVO-like 1 regulates progenitor cell fate in human trophoblast
10 development. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E6175-6184 (2015).
- 11 48. Chang, W.-L. *et al.* PLAC8, a new marker for human interstitial extravillous trophoblast cells,
12 promotes their invasion and migration. *Dev. Camb. Engl.* **145**, dev148932 (2018).
- 13 49. West, R. C. *et al.* Dynamics of trophoblast differentiation in peri-implantation-stage human
14 embryos. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 22635–22644 (2019).
- 15 50. Sheng, W. *et al.* LSD1 ablation stimulates anti-tumor immunity and enables checkpoint
16 blockade. *Cell* **174**, 549-563.e19 (2018).
- 17 51. Jeyarajah, M. J. *et al.* The multifaceted role of GCM1 during trophoblast differentiation in the
18 human placenta. *Proc. Natl. Acad. Sci. U. S. A.* **119**, e2203071119 (2022).
- 19 52. Nieto, M. A. The snail superfamily of zinc-finger transcription factors. *Nat. Rev. Mol. Cell*
20 *Biol.* **3**, 155–166 (2002).
- 21 53. Vasconcelos, S., Ramalho, C., Marques, C. J. & Doria, S. Altered expression of epigenetic
22 regulators and imprinted genes in human placenta and fetal tissues from second trimester
23 spontaneous pregnancy losses. *Epigenetics* **14**, 1234–1244 (2019).
- 24 54. Sasagawa, T. *et al.* HIF-2 α , but not HIF-1 α , mediates hypoxia-induced up-regulation of Flt-1
25 gene expression in placental trophoblasts. *Sci. Rep.* **8**, 17375 (2018).

- 1 55. Soares, M. J., Chakraborty, D., Kubota, K., Renaud, S. J. & Rumi, M. A. K. Adaptive
2 mechanisms controlling uterine spiral artery remodeling during the establishment of
3 pregnancy. *Int. J. Dev. Biol.* **58**, 247–259 (2014).
- 4 56. Warrington, N. M. *et al.* Maternal and fetal genetic effects on birth weight and their
5 relevance to cardio-metabolic risk factors. *Nat. Genet.* **51**, 804–814 (2019).
- 6 57. Pijnenborg, R., Vercruyssen, L. & Hanssens, M. The uterine spiral arteries in human
7 pregnancy: facts and controversies. *Placenta* **27**, 939–958 (2006).
- 8 58. Xie, W. *et al.* Epigenomic analysis of multilineage differentiation of human embryonic stem
9 cells. *Cell* **153**, 1134–1148 (2013).
- 10 59. Dixon, J. R. *et al.* Chromatin architecture reorganization during stem cell differentiation.
11 *Nature* **518**, 331–336 (2015).
- 12 60. Zhu, M. *et al.* Developmental clock and mechanism of de novo polarization of the mouse
13 embryo. *Science* **370**, eabd2703 (2020).
- 14 61. E Davies, J. *et al.* Epithelial-mesenchymal transition during extravillous trophoblast
15 differentiation. *Cell Adhes. Migr.* **10**, 310–321 (2016).
- 16 62. Fryer, B. H. & Simon, M. C. Hypoxia, HIF and the placenta. *Cell Cycle Georget. Tex* **5**, 495–
17 498 (2006).
- 18 63. Rajakumar, A. & Conrad, K. P. Expression, ontogeny, and regulation of hypoxia-inducible
19 transcription factors in the human placenta. *Biol. Reprod.* **63**, 559–569 (2000).
- 20 64. Fujii, T. *et al.* Enhanced HIF2 α expression during human trophoblast differentiation into
21 syncytiotrophoblast suppresses transcription of placental growth factor. *Sci. Rep.* **7**, 12455
22 (2017).
- 23 65. Loboda, A., Jozkowicz, A. & Dulak, J. HIF-1 and HIF-2 transcription factors--similar but not
24 identical. *Mol. Cells* **29**, 435–442 (2010).
- 25 66. Pugh, C. W. Modulation of the hypoxic response. *Adv. Exp. Med. Biol.* **903**, 259–271 (2016).
- 26 67. Johnson, E. A. HIF takes it up a notch. *Sci. Signal.* **4**, pe33 (2011).

- 1 68. Rajakumar, A. *et al.* Selective overexpression of the hypoxia-inducible transcription factor,
2 HIF-2alpha, in placentas from women with preeclampsia. *Biol. Reprod.* **64**, 499–506 (2001).
- 3 69. Dong, C. *et al.* Derivation of trophoblast stem cells from naïve human pluripotent stem cells.
4 *eLife* **9**, e52504 (2020).
- 5 70. Cinkornpumin, J. K. *et al.* Naive human embryonic stem cells can give rise to cells with a
6 trophoblast-like transcriptome and methylome. *Stem Cell Rep.* **15**, 198–213 (2020).
- 7 71. Corces, M. R. *et al.* An improved ATAC-seq protocol reduces background and enables
8 interrogation of frozen tissues. *Nat. Methods* **14**, 959–962 (2017).
- 9 72. Amemiya, H. M., Kundaje, A. & Boyle, A. P. The ENCODE Blacklist: Identification of
10 Problematic Regions of the Genome. *Sci. Rep.* **9**, 9354 (2019).
- 11 73. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic
12 features. *Bioinforma. Oxf. Engl.* **26**, 841–842 (2010).
- 13 74. Wolff, J. *et al.* Galaxy HiCExplorer 3: a web server for reproducible Hi-C, capture Hi-C and
14 single-cell Hi-C data analysis, quality control and visualization. *Nucleic Acids Res.* **48**,
15 W177–W184 (2020).
- 16 75. Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime cis-
17 regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576–589
18 (2010).
- 19 76. Practice Committee of the American Society for Reproductive Medicine. Electronic address:
20 asrm@asrm.org. Definitions of infertility and recurrent pregnancy loss: a committee opinion.
21 *Fertil. Steril.* **113**, 533–535 (2020).
- 22 77. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—
23 Gynecology. ACOG Practice Bulletin No. 200: Early Pregnancy Loss. *Obstet. Gynecol.* **132**,
24 e197–e207 (2018).
- 25 78. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587.e29
26 (2021).

- 1 79. Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq
2 data using regularized negative binomial regression. *Genome Biol.* **20**, 296 (2019).
- 3 80. Ahlmann-Eltze, C. & Huber, W. glmGamPoi: fitting Gamma-Poisson generalized linear
4 models on single cell count data. *Bioinforma. Oxf. Engl.* **36**, 5701–5702 (2021).
- 5 81. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
6 RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 7 82. Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count data:
8 removing the noise and preserving large differences. *Bioinforma. Oxf. Engl.* **35**, 2084–2092
9 (2019).
- 10 83. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for
11 interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–
12 15550 (2005).
- 13 84. Mootha, V. K. *et al.* PGC-1alpha-responsive genes involved in oxidative phosphorylation are
14 coordinately downregulated in human diabetes. *Nat. Genet.* **34**, 267–273 (2003).

15

16 **ACKNOWLEDGEMENTS**

17 We thank Stacy Oxley, Brandi Miller, and Nhu Bui for their administrative assistance,
18 Dan Louiselle, and Rebecca Biswell for their work in sample processing, Adam Walters and
19 Margaret Gibson for their work in library preparation and NGS and Bradley Belden and
20 Mackenzie Stevens for their work in clinical coordination. The research was supported by an
21 NRSA postdoctoral fellowship to K.M.V. from the National Institutes of Health (F32HD096809),
22 grants from the National Institutes of Health (HD020676, HD079363, HD099638, HD105734,
23 GM146966, HG012422), the Sosland Foundation, KAKENHI Grant Number 19H05757, and
24 AMED Grant Number JP22gm1310001. E.G holds the Roberta D. Harding & William F. Bradley,
25 Jr. Endowed Chair in Genomic Research.

26

1 **AUTHOR CONTRIBUTIONS**

2 K.M.V., H.O., T.A., M.J.S., and E.G. conceived and designed the research; K.M.V.,
3 E.M.D, A.M., R.M, and H.O. performed experiments; H.O., T.A., M.L., K.H., and C.M. provided
4 reagents. K.M.V, E.M.D., B.K., J.M.V., A.M., E.W., R.P.M., K.I., W.C., C.S-S., C.S., M.J.S., and
5 E.G. analyzed the data and interpreted results of experiments; K.M.V., B.K., C. S-S., M.J.S.,
6 and E.G. prepared figures and drafted manuscript; K.M.V., M.J.S., and E.G. edited and revised
7 manuscript; All authors approved the final version of manuscript.

8


9 **COMPETING INTEREST STATEMENT**

10 The authors declare no competing interest.

11


12

1 FIGURES




2
3 **Figure 1. Morphologic and transcriptomic changes during EVT cell differentiation from**
4 **human trophoblast stem (TS) cells. a) Simplified schematic depicting the three primary**

1 analyses (RNA-Seq, ATAC-Seq, and Hi-C) performed on human TS cell models in the stem
2 state and following eight days of extravillous trophoblast (**EVT**) cell differentiation. **b)** Principal
3 component analysis (PCA) plot depicting Stem (red), EVT Day 3 (green), EVT Day 6 (light blue),
4 and EVT Day 8 (dark blue) cell data of normalized read counts from RNA-Seq datasets. **c)** Log₂
5 fold-change values of normalized read counts from RNA-Seq of key EVT cell-specific transcripts
6 (*ASCL2*, *HLA-G*, *ITGA1*, and *MMP2*) at stem state and on day 3, 6, and 8 of EVT cell
7 differentiation compared to the stem state. **d)** Mean *HLA-G* expression/cell (top) and the
8 percentage of HLA-G positive cells detected by flow cytometry in CT27 (left) and CT29 (right)
9 cells in the stem state and on days 3, 6, and 8 of EVT cell differentiation (n=3-5 replicates per
10 group; ****p<0.0001). Graphs depict mean ± standard deviation (**SD**). **e)** Phase contrast images
11 of TS cells cultured in the stem state and on days 3, 6, and 8 of EVT cell differentiation in CT27
12 and CT29 cell lines. Stem state cells maintain a cobble-stone morphology and proliferate to
13 form discrete cell colonies. EVT cell differentiation is accompanied by cell elongation. Scale
14 bars represent 500 μm. **f)** Volcano plot depicting transcriptomic changes in EVT cells (CT27 and
15 CT29) on day 8 of differentiation compared to stem state cells (CT27 and CT29) measured by
16 RNA-Seq. Differentially expressed transcripts (absolute log₂ fold change >1, adjusted p value
17 <0.05) are labeled in red. Key stem state (*ELF5*, *EPCAM*, *F3*, *LIN28A*, *LRP2*, and *TEAD4*) and
18 EVT cell (*ASCL2*, *FSTL3*, *HLA-G*, *ITGA1*, *ITGA5*, *MMP2*, and *NOTUM*) transcripts are
19 annotated.
20




1
 2 **Figure 2. Validation of *in vitro* signatures of the TS model in single cell datasets from**
 3 **human placental samples. a)** UMAP plot depicting cell clustering from two publicly available,
 4 independent, single-cell RNA sequencing (**scRNA-Seq**) datasets from first-trimester
 5 placentas^{27,28}. Cell types are inferred using marker genes published previously²⁸ as decidual
 6 macrophages (**dM**), fetal (**Endo f**) and maternal endothelial cells (**Endo m**), epithelial glandular
 7 cells (**Epi**), extravillous trophoblast cells (**EVT**), fetal fibroblasts (**FB**), Hofbauer cells (**HB**),
 8 syncytiotrophoblast and villous cytotrophoblast (**SCT/VCT**) and cells not determined (**ND**). **b)**
 9 UMAP plots showing expression levels of EVT cell-specific genes detected in *in vitro* model.
 10 **c-e)** Plots depicting gene set enrichment analysis using three genes sets (each N=250) of
 11 genes significantly upregulated in **c)** SCT/VCT cells or **(d)**, EVT cells or **(e)** genes not differently
 12 expressed between SCT/VCT and EVT cells from scRNA-Seq data sets and tested for

1 enrichment for expression pattern in stem state (phenotype 1, CT27) and EVT cells (phenotype
2 0, CT27) from the *in vitro* TS model. Enrichment score (**ES**) reflects the degree of which each
3 gene set is overrepresented at the extremes (top or bottom) of genes expressed in phenotype 0
4 (EVT cells) versus phenotype 1 (stem state cells). Estimated significance of ES were accounted
5 for multiple testing and corresponded to **b**) Phenotype 0; FDR q value=NS; Phenotype 1; FDR q
6 value=0.00190 **c**) Phenotype 0; FDR q value=0.00196; Phenotype 1; FDR q value=NS and **d**)
7 Phenotype 0; FDR q value=NS; Phenotype 1; FDR q value=0.0016. FDR=false discovery rate;
8 NS=not significant.
9




1
2 **Figure 3. EVT cell differentiation drives global changes in chromatin accessibility. a)** bar
3 graphs depicting the fraction of chromatin accessible regions across five defined genomic

1 regions (e.g., transcription termination site (**TTS**), promoter-transcription start site (**TSS**), intron,
2 intergenic, and exon regions). Chromatin accessible regions were identified by ATAC-Seq and
3 are classified into three primary groups: regions that are 1) unique to stem state cells, 2) shared
4 between stem and EVT cells or 3) unique to EVT cells. **b)** Tornado plots showing the density of
5 chromatin accessible regions within 10 kb of TSS that are unique to EVT cells, unique to stem
6 state cells, or shared between the two cell states. Colorimetric scale (red to blue) represents
7 coverage intensity. **c)** Tornado plots showing ATAC-Seq coverage in peak regions from CHIP-
8 Seq of H3K4me3 and H3K27ac in EVT and stem state cells, respectively. Colorimetric scale
9 (red to blue) represents coverage intensity **(d, e)** bar graphs depicting the fraction of
10 differentially enriched chromatin accessible regions identified by ATAC-Seq in stem state **(d)** or
11 EVT **(e)** cells across three chromatin states defined by histone modifications: H3K4me3
12 (putative poised promoters), H3K27ac (active enhancers) and H3K4me3+H3K27ac (active
13 promoters). **f)** Schematic depicting regulatory regions selected for transcription factor (**TF**)
14 analysis and motifs for three top TFs identified in the analysis,
15




1
2 **Figure 4. Long-range chromatin interactions in stem state and EVT cells.** a) Hi-C contact
3 maps at 5kb resolution across all chromosomes in stem state and EVT cells. b, c) Hi-C contact

1 maps zoomed in to 5kb resolution on **b)** chromosome 7 and **c)** *DLX6* locus for stem state and
2 EVT cells. Identified loops are marked as black (all) or blue (cell-specific) boxes on either side of
3 the map. RefSeq genes (green track) and ATAC-Seq (blue tracks, counts per million mapped
4 reads, y-axis) are used for annotation. Yellow box indicates a EVT cell-specific loop at
5 chromatin accessible regions specific to EVT at the *DLX6* locus. **d)** Aggregate plot depicting
6 EVT chromatin loop interactions at 9,334 EVT cell differentially accessed chromatin regions
7 centered between total number of bins used in the submatrix (N=20). Enrichment is calculated
8 based on transformation of observed to expected interactions and shown from low (0.8) to high
9 (2.2) enrichment as illustrated using blue to red color scale. **e)** Hi-C, RNA-Seq, ATAC-Seq, and
10 H3K4me3 and H3K27ac ChIP-Seq assessments performed in CT27 cells differentiated into
11 EVT cells (top panel) or maintained in the stem state (bottom panel). Regulatory elements near
12 *DLX5/DLX6* are shown and include Hi-C loops (red, both loop anchors in view; blue, loop
13 anchors out of view), RNA-Seq (transcripts per million, y-axis), ATAC-Seq (counts per million
14 mapped reads, y-axis), H3K4me3, and H3K27ac ChIP-Seq (counts per million mapped reads,
15 y-axis). All datasets are shown in individual tracks. Super-enhancers (SE, red) and differentially
16 bound regions (**DB**, blue) are specific to the EVT cell state. Key regulatory regions are
17 highlighted in yellow.
18



1
2 **Figure 5. Expression of transcription factors in single EVT cells derived from human**
3 **placenta.** Data from two publicly available, independent, single-cell RNA sequencing (scRNA-
4 Seq) datasets from first trimester placentas^{27,28} is used and cell types are inferred using marker
5 genes published previously²⁸ as decidual macrophages (**dM**), fetal (**Endo f**) and maternal


1 endothelial cells (**Endo m**), epithelial glandular cells (**Epi**), extravillous trophoblast cells (**EVT**),
2 fetal fibroblasts (**FB**), Hofbauer cells (**HB**), syncytiotrophoblast and villous cytotrophoblast
3 (**SCT/VCT**) and cells not determined (**ND**). Single cell expression values for five transcription
4 factors (*ASCL2*; *DLX6*; *EPAS1*, *MYCN* and *SNAI1*) shown in **a**) Violin plots comparing EVT cells
5 (orange) with syncytiotrophoblast (**SCT**) and villous cytotrophoblast cells (**VCT**) combined
6 (turquoise) and **b**) UMAP feature plots.
7



1
 2 **Figure 6. Functional assessment of *TFAP2C* actions in trophoblast cell development.**

3 **a)** Representative human placental tissue specimen (12 weeks of gestation) probed for
 4 *TFAP2C*, *CDH1*, and *PLAC8* transcripts using *in situ* hybridization. DAPI labels cell nuclei.
 5 Overlay of merged immunofluorescence images: *TFAP2C* (red), DAPI (gray), and either *CDH1*


1 (green) or *PLAC8* (green), respectively. Scale bars represent 50 μm (*CDH1* image panels) and
2 100 μm (*PLAC8* image panels). **b)** RT-qPCR measurement of *TFAP2C* normalized to *POLR2A*
3 in stem and EVT cells (ns=not significant $p>0.05$; $n=4$ per group). **c)** *TFAP2C* (50 kDa) and
4 *GAPDH* (37 kDa) proteins in stem and EVT cells assessed by western blot analysis. **d)** Log_2
5 fold-change values of normalized read counts of *TFAP2C* from RNA-Seq in stem state and days
6 3, 6, and 8 of EVT cell differentiation compared to the Stem state. **e)** RT-qPCR measurement of
7 *TFAP2C* normalized to *POLR2A* in stem state cells transduced with lentivirus containing a
8 control shRNA (**shC**) or a *TFAP2C*-specific shRNA (**shTFAP2C**; $n=4$ per group; $**p<0.01$). **f)**
9 *TFAP2C* (50 kDa) and *GAPDH* (37 kDa) proteins in stem state cells transduced with shC or
10 shTFAP2C and assessed by western blot. **g)** Phase contrast images of stem state cells
11 transduced with shC or shTFAP2C. Scale bar represents 250 μm . **h)** Heat map based on
12 scaled, normalized counts of selected differentially expressed transcripts generated from RNA-
13 Seq in shC (control, **Ctrl**; orange) or shTFAP2C (knockdown, **KD**; blue) transduced cells.
14 Transcripts are clustered into four groups including cell cycle (purple), EVT-specific (pink), stem
15 state-specific (green), or other (blue). *Depict genes identified as direct targets of *TFAP2C*
16 based on CHIP-Seq analysis in TS cells. Graphs in panels B and E depict mean \pm standard
17 deviation.
18



1
 2 **Figure 7. Expression patterns of *SNAI1*, and *EPAS1*.** a) Human placental tissue specimen
 3 (12 weeks of gestation) probed for *SNAI1*, *EPAS1*, *CDH1* and *PLAC8* transcripts using *in situ*


1 hybridization. DAPI labels cell nuclei. Overlay of merged immunofluorescence images: *SNAI1*
2 (red), or *EPAS1* (red), with DAPI (gray), and *CDH1* (green) or *PLAC8* (green). Scale bars
3 represent 100 μm in *CDH1* image panels and 50 μm in *PLAC8* image panels. **b)** Log₂ fold-
4 change values of normalized read counts of *SNAI1* and *EPAS1* from RNA-Seq in stem state
5 and days 3, 6, and 8 of EVT cell differentiation compared to the Stem state. **c)** RT-qPCR
6 measure of *SNAI1* (Stem n=6; EVT n=4), and *EPAS1* (n=6 per group) normalized to *B2M* in
7 stem and EVT cells (*p<0.05 and ****p<0.0001). Graphs depict mean \pm standard deviation (SD).
8 **d)** *SNAI1* (29 kDa), *EPAS1* (120 kDa), and *GAPDH* (37 kDa) protein in stem and EVT cells
9 assessed by western blot analysis.

10



1
 2 **Figure 8. Functional investigation of *SNAI1* on EVT cell differentiation in CT27 cells. a)**
 3 RT-qPCR measurement of *SNAI1* (n=5 per group) normalized to *B2M* in EVT cells differentiated
 4 from stem state cells transduced with lentivirus containing a control shRNA (**shC**) or *SNAI1*-
 5 specific shRNA (**shSNAI1**). Graph depicts mean \pm standard deviation. **b)** *SNAI1* (29 kDa) and
 6 GAPDH (37 kDa) protein in EVT cells from shC control or shSNAI1 treated cells measured by

1 western blot. **c)** Phase contrast images of shC control or shSNAI1 EVT cells following eight
2 days of differentiation. Scale bars represent 500 μm . **d)** Heat map based on scaled, normalized
3 counts of selected transcripts generated from RNA-Seq in shC (control, **Ctrl**; orange) or
4 shSNAI1 (knockdown, **KD**; blue) transduced cells (n=3 per group). Transcripts are clustered into
5 three groups including EVT-specific (pink), EVT interferon (**IFN**) responsive (purple), or stem
6 state-specific (green). **e)** Hi-C, RNA-Seq, ATAC-Seq, and H3K4me3 and H3K27ac ChIP-Seq
7 assessments performed in CT27 cells differentiated into EVT cells (top panel) or maintained in
8 the stem state (bottom panel). Identified regulatory elements near *SNAI1* are highlighted in
9 orange and overlap Hi-C loops (red, both loop anchors in view; blue, loop anchors out of view),
10 open chromatin by ATAC-Seq (counts per million mapped reads, y-axis), and promoter or
11 enhancer mark by H3K4me3, or H3K27ac ChIP-Seq, respectively (counts per million mapped
12 reads, y-axis). Expression level is shown by RNA-Seq (transcripts per million, y-axis). All
13 datasets are shown in individual tracks. Super-enhancers (**SE**, red) and differentially bound
14 regions (**DB**, blue) are specific to the EVT cell state.
15



1
 2 **Figure 9. Functional investigation of *EPAS1* on EVT cell differentiation in CT27 cells. a)**
 3 RT-qPCR measurement of *EPAS1* (n=3 per group) normalized to *B2M* in EVT cells

1 differentiated from stem state cells transduced with lentivirus containing a control shRNA (**shC**)
2 or a *EPAS1*-specific shRNA (**shEPAS1**). Graph depicts mean \pm standard deviation. **b)** *EPAS1*
3 (120 kDa) and GAPDH (37 kDa) protein in EVT cells from shC control or shEPAS1 treated cells
4 measured by western blot. **c)** Phase contrast images of shC control or shEPAS1 EVT cells
5 following eight days of differentiation. Scale bars represent 500 μ m. **d)** Heat map based on
6 scaled, normalized counts of selected transcripts generated from RNA-Seq in shC control (**Ctrl**,
7 orange) or shEPAS1 (**KD**, blue) transduced cells (n=3 per group). Transcripts are clustered into
8 two groups including EVT-specific (pink) or stem state-specific (green). **e)** Hi-C, RNA-Seq,
9 ATAC-Seq, and H3K4me3 and H3K27ac ChIP-Seq assessments performed in CT27 cells
10 differentiated into EVT cells (top panel) or maintained in the stem state (bottom panel). Identified
11 regulatory elements near *EPAS1* are highlighted in orange and overlap Hi-C loops (red, both
12 loop anchors in view; blue, loop anchors out of view), open chromatin by ATAC-Seq (counts per
13 million mapped reads, y-axis), and promoter or enhancer mark by H3K4me3, or H3K27ac ChIP-
14 Seq, respectively (counts per million mapped reads, y-axis). Expression level is shown by RNA-
15 Seq (transcripts per million, y-axis). All datasets are shown in individual tracks. Super-
16 enhancers (**SE**, red) and differentially bound regions (**DB**, blue) are specific to the EVT cell
17 state. SNPs associated with pregnancy loss (PL) or birth weight (BW) in large genome-wide
18 association studies (GWAS) are shown in brown circles. **f)** Violin plot of *EPAS1* expression in
19 EVT cells generated from single-cell RNA-Seq analysis of human first trimester placental
20 samples derived from control patients (**Control**, orange) and patients experiencing recurrent
21 pregnancy loss (**RPL**, turquoise). The y-axis represents normalized and natural log transformed
22 *EPAS1* expression levels. **g)** Schematic of transcriptional regulatory hierarchy controlling
23 extravillous trophoblast (**EVT**) cell differentiation. *TFAP2C* is important for maintenance of
24 human TS cells in the stem state and transition to the differentiation state. *EPAS1* is induced
25 upon EVT cell differentiation and acts as an upstream regulator of several EVT cell-specific
26 transcription factors, including *ASCL2*, *SNAI1*, *DLX6*, and *MYCN*.